Π‘ΠΎΡΠ΅ΡΠ°Π½ΠΈΠ΅ Ρ ΡΠΎΠ½ΠΈΡΠ΅ΡΠΊΠΎΠΉ ΡΠ΅ΡΠ΄Π΅ΡΠ½ΠΎΠΉ Π½Π΅Π΄ΠΎΡΡΠ°ΡΠΎΡΠ½ΠΎΡΡΠΈ ΠΈ ΡΠ°Ρ Π°ΡΠ½ΠΎΠ³ΠΎ Π΄ΠΈΠ°Π±Π΅ΡΠ° 2-Π³ΠΎ ΡΠΈΠΏΠ°: ΠΎΠ±ΡΠ°Ρ Ρ Π°ΡΠ°ΠΊΡΠ΅ΡΠΈΡΡΠΈΠΊΠ° Π±ΠΎΠ»ΡΠ½ΡΡ , ΠΊΠ»ΠΈΠ½ΠΈΡΠ΅ΡΠΊΠ°Ρ ΠΊΠ°ΡΡΠΈΠ½Π°, ΠΏΡΠΎΠ±Π»Π΅ΠΌΡ Π»Π΅ΡΠ΅Π½ΠΈΡ ΠΈ ΠΏΡΠΎΠ³Π½ΠΎΠ·Π°
ΠΠ°ΡΠΈΠ΅Π½ΡΡ Ρ ΡΠΎΡΠ΅ΡΠ°Π½ΠΈΠ΅ΠΌ Π₯Π‘Π ΠΈ Π‘Π 2 ΡΠΈΠΏΠ° ΠΈΠΌΠ΅ΡΡ Π½Π΅ ΡΠΎΠ»ΡΠΊΠΎ Π±ΠΎΠ»Π΅Π΅ Π²ΡΡΠΎΠΊΠΈΠΉ ΡΡΠΎΠ²Π΅Π½Ρ Π³Π»ΠΈΠΊΠ΅ΠΌΠΈΠΈ ΠΈ ΡΠ°ΡΡΠΎΡΡ Π³Π»ΡΠΊΠΎΠ·ΡΡΠΈΠΈ, Π½ΠΎ ΠΈ ΡΠΊΠ»ΠΎΠ½Π½ΠΎΡΡΡ ΠΊ ΠΎΠΆΠΈΡΠ΅Π½ΠΈΡ (Π΄ΠΎΡΡΠΎΠ²Π΅ΡΠ½ΠΎ ΠΏΠΎΠ²ΡΡΠ΅Π½Π½ΡΠΉ ΠΠΠ’) ΠΈ Π½Π°ΡΡΡΠ΅Π½ΠΈΡ ΡΡΠ½ΠΊΡΠΈΠΈ ΠΏΠΎΡΠ΅ΠΊ, ΡΡΠΎ Ρ Π°ΡΠ°ΠΊΡΠ΅ΡΠΈΠ·ΡΠ΅ΡΡΡ ΠΏΠΎΠ²ΡΡΠ΅Π½Π½ΡΠΌ ΡΡΠΎΠ²Π½Π΅ΠΌ ΠΊΡΠ΅Π°ΡΠΈΠ½ΠΈΠ½Π° ΠΈ ΠΌΠΈΠΊΡΠΎΠ°Π»ΡΠ±ΡΠΌΠΈΠ½ΡΡΠΈΠΈ, Ρ. Π΅. ΡΠ°ΠΌΠ° Π₯Π‘Π Π½Π΅ «ΠΌΠ°ΡΠΊΠΈΡΡΠ΅Ρ» ΠΊΠ»ΠΈΠ½ΠΈΡΠ΅ΡΠΊΠΈΡ ΠΈ Π»Π°Π±ΠΎΡΠ°ΡΠΎΡΠ½ΡΡ ΠΏΡΠΎΡΠ²Π»Π΅Π½ΠΈΠΉ Π‘Π 2 ΡΠΈΠΏΠ°, Π° Π² Π½Π°ΡΡΡΠ΅Π½ΠΈΠ΅ ΡΡΠ½ΠΊΡΠΈΠΈ ΠΏΠΎΡΠ΅ΠΊ Π²Π½ΠΎΡΡΡ Π²ΠΊΠ»Π°Π΄ ΠΎΠ±Π° ΠΊΠΎΠΌΠΏΠΎΠ½Π΅Π½ΡΠ°… Π§ΠΈΡΠ°ΡΡ Π΅ΡΡ >
- Π‘ΠΎΠ΄Π΅ΡΠΆΠ°Π½ΠΈΠ΅
- ΠΡΠ΄Π΅ΡΠΆΠΊΠ°
- ΠΠΈΡΠ΅ΡΠ°ΡΡΡΠ°
- ΠΡΡΠ³ΠΈΠ΅ ΡΠ°Π±ΠΎΡΡ
- ΠΠΎΠΌΠΎΡΡ Π² Π½Π°ΠΏΠΈΡΠ°Π½ΠΈΠΈ
Π‘ΠΎΠ΄Π΅ΡΠΆΠ°Π½ΠΈΠ΅
- Π£ΡΠ»ΠΎΠ²Π½ΡΠ΅ ΠΎΠ±ΠΎΠ·Π½Π°ΡΠ΅Π½ΠΈΡ
Π‘ΠΎΡΠ΅ΡΠ°Π½ΠΈΠ΅ Ρ ΡΠΎΠ½ΠΈΡΠ΅ΡΠΊΠΎΠΉ ΡΠ΅ΡΠ΄Π΅ΡΠ½ΠΎΠΉ Π½Π΅Π΄ΠΎΡΡΠ°ΡΠΎΡΠ½ΠΎΡΡΠΈ ΠΈ ΡΠ°Ρ Π°ΡΠ½ΠΎΠ³ΠΎ Π΄ΠΈΠ°Π±Π΅ΡΠ° 2-Π³ΠΎ ΡΠΈΠΏΠ°: ΠΎΠ±ΡΠ°Ρ Ρ Π°ΡΠ°ΠΊΡΠ΅ΡΠΈΡΡΠΈΠΊΠ° Π±ΠΎΠ»ΡΠ½ΡΡ , ΠΊΠ»ΠΈΠ½ΠΈΡΠ΅ΡΠΊΠ°Ρ ΠΊΠ°ΡΡΠΈΠ½Π°, ΠΏΡΠΎΠ±Π»Π΅ΠΌΡ Π»Π΅ΡΠ΅Π½ΠΈΡ ΠΈ ΠΏΡΠΎΠ³Π½ΠΎΠ·Π° (ΡΠ΅ΡΠ΅ΡΠ°Ρ, ΠΊΡΡΡΠΎΠ²Π°Ρ, Π΄ΠΈΠΏΠ»ΠΎΠΌ, ΠΊΠΎΠ½ΡΡΠΎΠ»ΡΠ½Π°Ρ)
Π¦Π΅Π»Ρ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΡ. 8.
ΠΠ°Π΄Π°ΡΠΈ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΡ. 8.
ΠΠ°ΡΡΠ½Π°Ρ Π½ΠΎΠ²ΠΈΠ·Π½Π°.8.
ΠΡΠ°ΠΊΡΠΈΡΠ΅ΡΠΊΠ°Ρ Π·Π½Π°ΡΠΈΠΌΠΎΡΡΡ.10.
ΠΡΠ½ΠΎΠ²Π½ΡΠ΅ ΠΏΠΎΠ»ΠΎΠΆΠ΅Π½ΠΈΡ, Π²ΡΠ½ΠΎΡΠΈΠΌΡΠ΅ Π½Π° Π·Π°ΡΠΈΡΡ.10.
ΠΠ½Π΅Π΄ΡΠ΅Π½ΠΈΠ΅ Π² ΠΏΡΠ°ΠΊΡΠΈΠΊΡ.11.
ΠΠΎΠ»ΠΈΡΠ΅ΡΡΠ²ΠΎ ΠΎΠΏΡΠ±Π»ΠΈΠΊΠΎΠ²Π°Π½Π½ΡΡ ΡΠ°Π±ΠΎΡ ΠΈ ΡΠΎΠΎΠ±ΡΠ΅Π½ΠΈΠΉ ΠΏΠΎ ΡΠ΅ΠΌΠ΅ Π΄ΠΈΡΡΠ΅ΡΡΠ°ΡΠΈΠΈ. 11.
Π²ΡΠ²ΠΎΠ΄Ρ.
1. ΠΡΠ½ΠΎΠ²Π½ΡΠΌΠΈ Ρ Π°ΡΠ°ΠΊΡΠ΅ΡΠΈΡΡΠΈΠΊΠ°ΠΌΠΈ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² Ρ ΡΠΎΡΠ΅ΡΠ°Π½ΠΈΠ΅ΠΌ Π₯Π‘Π ΠΈ Π‘Π 2 ΡΠΈΠΏΠ°, Π² ΡΡΠ°Π²Π½Π΅Π½ΠΈΠΈ Ρ Π±ΠΎΠ»ΡΠ½ΡΠΌΠΈ Ρ Π₯Π‘Π, ΠΏΠΎ Π΄Π°Π½Π½ΡΠΌ ΠΊΠ°ΠΊ ΠΏΡΠΎ-, ΡΠ°ΠΊ ΠΈ ΡΠ΅ΡΡΠΎΡΠΏΠ΅ΠΊΡΠΈΠ²Π½ΠΎΠ³ΠΎ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΠΉ ΡΠ²Π»ΡΡΡΡΡ: ΠΏΠΎΠΆΠΈΠ»ΠΎΠΉ Π²ΠΎΠ·ΡΠ°ΡΡ, ΠΆΠ΅Π½ΡΠΊΠΈΠΉ ΠΏΠΎΠ», Π° Π³ ΡΠ°ΠΊΠΆΠ΅ Π΄ΠΎΡΡΠΎΠ²Π΅ΡΠ½ΠΎ Π±ΠΎΠ»Π΅Π΅ ΡΠ°ΡΡΠ°Ρ Π²ΡΡΡΠ΅ΡΠ°Π΅ΠΌΠΎΡΡΡ ΠΠΠ‘ (ΠΈ ΠΏΠΎΡΡΠΈΠ½ΡΠ°ΡΠΊΡΠ½ΠΎΠ³ΠΎ ΠΊΠ°ΡΠ΄ΠΈΠΎΡΠΊΠ»Π΅ΡΠΎΠ·Π°) ΠΈ ΠΠ, Π² ΠΊΠ°ΡΠ΅ΡΡΠ²Π΅ Π³Π»Π°Π²Π½ΡΡ ΡΡΠΈΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΈΡ ΠΏΡΠΈΡΠΈΠ½ Π΄Π΅ΠΊΠΎΠΌΠΏΠ΅Π½ΡΠ°ΡΠΈΠΈ. ΠΠΎΠ»Π΅Π΅ ΡΠ°ΡΡΠΎ ΡΠΎΡ ΡΠ°Π½ΡΠ΅ΡΡΡ ΡΠΈΠ½ΡΡΠΎΠ²ΡΠΉ ΡΠΈΡΠΌ.
2. ΠΡΠΈΡΠΎΠ΅Π΄ΠΈΠ½Π΅Π½ΠΈΠ΅ Π‘Π 2 ΡΠΈΠΏΠ° ΠΊ Π₯Π‘Π Π»ΠΈΡΡ ΡΠ²Π΅Π»ΠΈΡΠΈΠ²Π°Π΅Ρ ΡΡΠ΅ΠΏΠ΅Π½Ρ Π΄Π΅ΠΊΠΎΠΌΠΏΠ΅Π½ΡΠ°ΡΠΈΠΈ (ΠΏΡΠΎΡΠ΅Π½Ρ Π±ΠΎΠ»ΡΠ½ΡΡ Ρ III Π€Π ΡΠ²Π΅Π»ΠΈΡΠΈΠ²Π°Π΅ΡΡΡ Ρ 49,5% Π΄ΠΎ 73,2%) ΠΈ Π½Π΅ ΠΎΠΊΠ°Π·ΡΠ²Π°Π΅Ρ Π·Π½Π°ΡΠΈΠΌΠΎΠ³ΠΎ Π²Π»ΠΈΡΠ½ΠΈΡ Π½ΠΈ Π½Π° ΡΠΈΡΡΠΎΠ»ΠΈΡΠ΅ΡΠΊΡΡ, Π½ΠΈ Π½Π° Π΄ΠΈΠ°ΡΡΠΎΠ»ΠΈΡΠ΅-ΡΠΊΡΡ ΡΡΠ½ΠΊΡΠΈΡ ΠΠ, Ρ ΠΎΡΡ ΠΊΠ°ΡΠ΅ΡΡΠ²ΠΎ ΠΆΠΈΠ·Π½ΠΈ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² ΠΏΡΠΈ ΡΠΎΡΠ΅ΡΠ°Π½ΠΈΠΈ Π₯Π‘Π ΠΈ Π‘Π 2 ΡΠΈΠΏΠ° Π΄ΠΎΡΡΠΎΠ²Π΅ΡΠ½ΠΎ ΡΡ ΡΠ΄ΡΠ°Π΅ΡΡΡ Π² ΡΡΠ°Π²Π½Π΅Π½ΠΈΠΈ Ρ Π±ΠΎΠ»ΡΠ½ΡΠΌΠΈ Ρ «ΠΈΠ·ΠΎΠ»ΠΈΡΠΎΠ²Π°Π½Π½ΠΎΠΉ» Π₯Π‘Π.
3. ΠΠ»ΠΈΡΠ΅Π»ΡΠ½ΠΎΡΡΡ Π΄ΠΈΠ°Π±Π΅ΡΠ° Π±ΠΎΠ»Π΅Π΅ 10 Π»Π΅Ρ ΠΌΠ°ΠΊΡΠΈΠΌΠ°Π»ΡΠ½ΠΎ ΡΡ ΡΠ΄ΡΠ°Π΅Ρ ΠΊΠ»ΠΈΠ½ΠΈΡΠ΅ΡΠΊΠΎΠ΅ ΡΠ΅ΡΠ΅Π½ΠΈΠ΅ Π±ΠΎΠ»Π΅Π·Π½ΠΈ Ρ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² Ρ Π₯Π‘Π ΠΈ ΠΏΡΠΈΠ²ΠΎΠ΄ΠΈΡ ΠΊ ΠΏΠΎΡΠ°ΠΆΠ΅Π½ΠΈΡ ΠΎΡΠ³Π°Π½ΠΎΠ² — ΠΌΠΈΡΠ΅Π½Π΅ΠΉ (ΡΠ΅ΡΠ΄ΡΠ°, ΠΏΠΎΡΠ΅ΠΊ). ΠΡΠΈ ΡΡΠΎΠΌ ΠΌΠ°ΠΊΡΠΈΠΌΠ°Π»ΡΠ½ΠΎ Π²ΠΎΠ·ΡΠ°ΡΡΠ°Π΅Ρ ΡΠΎΠ»Ρ ΠΏΡΠΈΡΠΎΠ΅Π΄ΠΈΠ½ΠΈΠ²ΡΠ΅ΠΉΡΡ ΠΠ ΠΈ ΠΏΠΎΠ΄ΡΠ΅ΠΌΠΎΠ² ΠΠ, Π½Π°ΡΠΈΠ½Π°Π΅Ρ ΡΠ½ΠΈΠΆΠ°ΡΡΡΡ ΡΠΈΡΡΠΎΠ»ΠΈΡΠ΅ΡΠΊΠ°Ρ ΡΡΠ½ΠΊΡΠΈΡ ΡΠ΅ΡΠ΄ΡΠ° ΠΈ Π΄ΠΎΡΡΠΎΠ²Π΅ΡΠ½ΠΎ ΠΏΠΎΠ²ΡΡΠ°Π΅ΡΡΡ ΡΡΠ΅ΠΏΠ΅Π½Ρ Π°Π»ΡΠ±ΡΠΌΠΈΠ½ΡΡΠΈΠΈ, Ρ. Π΅. ΡΡ ΡΠ΄ΡΠ°Π΅ΡΡΡ ΡΡΠ½ΠΊΡΠΈΡ ΠΏΠΎΡΠ΅ΠΊ. Π’ΠΎΠ»ΡΠΊΠΎ Π΄Π»ΠΈΡΠ΅Π»ΡΠ½ΠΎ ΡΡΡΠ΅ΡΡΠ²ΡΡΡΠΈΠΉ Π‘Π 2 ΡΠΈΠΏΠ° ΡΠ΅Π°Π»ΡΠ½ΠΎ ΡΡ ΡΠ΄ΡΠ°Π΅Ρ ΠΊΠ»ΠΈΠ½ΠΈΡΠ΅ΡΠΊΠΎΠ΅ ΡΠ΅ΡΠ΅Π½ΠΈΠ΅ Π₯Π‘Π.
4. ΠΠ°ΡΠΈΠ΅Π½ΡΡ Ρ ΡΠΎΡΠ΅ΡΠ°Π½ΠΈΠ΅ΠΌ Π₯Π‘Π ΠΈ Π‘Π 2 ΡΠΈΠΏΠ° ΠΈΠΌΠ΅ΡΡ Π½Π΅ ΡΠΎΠ»ΡΠΊΠΎ Π±ΠΎΠ»Π΅Π΅ Π²ΡΡΠΎΠΊΠΈΠΉ ΡΡΠΎΠ²Π΅Π½Ρ Π³Π»ΠΈΠΊΠ΅ΠΌΠΈΠΈ ΠΈ ΡΠ°ΡΡΠΎΡΡ Π³Π»ΡΠΊΠΎΠ·ΡΡΠΈΠΈ, Π½ΠΎ ΠΈ ΡΠΊΠ»ΠΎΠ½Π½ΠΎΡΡΡ ΠΊ ΠΎΠΆΠΈΡΠ΅Π½ΠΈΡ (Π΄ΠΎΡΡΠΎΠ²Π΅ΡΠ½ΠΎ ΠΏΠΎΠ²ΡΡΠ΅Π½Π½ΡΠΉ ΠΠΠ’) ΠΈ Π½Π°ΡΡΡΠ΅Π½ΠΈΡ ΡΡΠ½ΠΊΡΠΈΠΈ ΠΏΠΎΡΠ΅ΠΊ, ΡΡΠΎ Ρ Π°ΡΠ°ΠΊΡΠ΅ΡΠΈΠ·ΡΠ΅ΡΡΡ ΠΏΠΎΠ²ΡΡΠ΅Π½Π½ΡΠΌ ΡΡΠΎΠ²Π½Π΅ΠΌ ΠΊΡΠ΅Π°ΡΠΈΠ½ΠΈΠ½Π° ΠΈ ΠΌΠΈΠΊΡΠΎΠ°Π»ΡΠ±ΡΠΌΠΈΠ½ΡΡΠΈΠΈ, Ρ. Π΅. ΡΠ°ΠΌΠ° Π₯Π‘Π Π½Π΅ «ΠΌΠ°ΡΠΊΠΈΡΡΠ΅Ρ» ΠΊΠ»ΠΈΠ½ΠΈΡΠ΅ΡΠΊΠΈΡ ΠΈ Π»Π°Π±ΠΎΡΠ°ΡΠΎΡΠ½ΡΡ ΠΏΡΠΎΡΠ²Π»Π΅Π½ΠΈΠΉ Π‘Π 2 ΡΠΈΠΏΠ°, Π° Π² Π½Π°ΡΡΡΠ΅Π½ΠΈΠ΅ ΡΡΠ½ΠΊΡΠΈΠΈ ΠΏΠΎΡΠ΅ΠΊ Π²Π½ΠΎΡΡΡ Π²ΠΊΠ»Π°Π΄ ΠΎΠ±Π° ΠΊΠΎΠΌΠΏΠΎΠ½Π΅Π½ΡΠ° ΡΠΎΡΠ΅ΡΠ°Π½Π½ΠΎΠΉ ΠΏΠ°ΡΠΎΠ»ΠΎΠ³ΠΈΠΈ.
5. ΠΠ΅ΡΠΌΠΎΡΡΡ Π½Π° Ρ Π°ΡΠ°ΠΊΡΠ΅ΡΠ½ΠΎΠ΅ Π΄Π»Ρ Π₯Π‘Π Π½Π°ΡΡΡΠ΅Π½ΠΈΠ΅ ΡΡΠ½ΠΊΡΠΈΠΈ ΠΏΠ΅ΡΠ΅Π½ΠΈ (Π² ΡΠΎΠΌ ΡΠΈΡΠ»Π΅ ΡΠΏΠΎΡΠΎΠ±Π½ΠΎΡΡΠΈ ΠΊ ΡΠΈΠ½ΡΠ΅Π·Ρ Ρ ΠΎΠ»Π΅ΡΡΠ΅ΡΠΈΠ½Π°), ΠΏΡΠΈ ΡΠΎΡΠ΅ΡΠ°Π½ΠΈΠΈ Π΄Π΅ΠΊΠΎΠΌΠΏΠ΅Π½ΡΠ°ΡΠΈΠΈ Ρ Π‘Π 2 ΡΠΈΠΏΠ° ΠΏΡΠΎΡΠ²Π»ΡΡΡΡΡ ΡΠΈΠΏΠΈΡΠ½ΡΠ΅ ΡΠ΅ΡΡΡ Π΄ΠΈΠ°Π±Π΅ΡΠΈΡΠ΅ΡΠΊΠΎΠΉ Π΄ΠΈΡΠ»ΠΈΠΏΠΈΠ΄Π΅ΠΌΠΈΠΈ Π² Π²ΠΈΠ΄Π΅ ΠΏΠΎΠ²ΡΡΠ΅Π½ΠΈΡ ΡΡΠΈΠ³Π»ΠΈΡΠ΅ΡΠΈΠ΄ΠΎΠ² ΠΈ ΠΎΠ±ΡΠ΅Π³ΠΎ Ρ ΠΎΠ»Π΅ΡΡΠ΅ΡΠΈΠ½Π° ΠΏΡΠΈ Π΄ΠΎΡΡΠΎΠ²Π΅ΡΠ½ΠΎΠΌ ΡΠ²Π΅Π»ΠΈΡΠ΅Π½ΠΈΠΈ Ρ ΠΎΠ»Π΅ΡΡΠ΅ΡΠΈΠ½Π° ΠΠΠΠΠ ΠΈ ΡΠ½ΠΈΠΆΠ΅Π½ΠΈΠΈ Π°Π½ΡΠΈΠ°ΡΠ΅ΡΠΎΠ³Π΅Π½Π½ΠΎΠ³ΠΎ Ρ ΠΎΠ»Π΅ΡΡΠ΅ΡΠΈΠ½Π° ΠΠΠΠ. Β¦
6. ΠΡΠΈΠΌΠ΅Π½Π΅Π½ΠΈΠ΅ ΠΠΠΠ€ Π² ΠΊΠΎΠΌΠΏΠ»Π΅ΠΊΡΠ½ΠΎΠΉ ΡΠ΅ΡΠ°ΠΏΠΈΠΈ Π±ΠΎΠ»ΡΠ½ΡΡ Ρ ΡΠΎΡΠ΅ΡΠ°Π½ΠΈΠ΅ΠΌ Π₯Π‘Π ΠΈ Π‘Π 2 ΡΠΈΠΏΠ° ΠΎΠΊΠ°Π·Π°Π»ΠΎΡΡ Π²ΡΡΠΎΠΊΠΎ ΡΡΡΠ΅ΠΊΡΠΈΠ²Π½ΡΠΌ ΠΈ ΠΏΠΎΠ·Π²ΠΎΠ»ΠΈΠ»ΠΎ ΠΎΠ΄Π½ΠΎΠ²ΡΠ΅ΠΌΠ΅Π½Π½ΠΎ ΡΠΌΠ΅Π½ΡΡΠΈΡΡ ΡΠΈΠΏΠΈΡΠ½ΡΠ΅ ΠΏΡΠΎΡΠ²Π»Π΅Π½ΠΈΡ Π₯Π‘Π, Π° ΡΠ°ΠΊΠΆΠ΅ ΠΈ Π‘Π 2 ΡΠΈΠΏΠ° Π² Π²ΠΈΠ΄Π΅ Π½ΠΎΡΠΌΠ°Π»ΠΈΠ·Π°ΡΠΈΠΈ ΡΡΠΎΠ²Π½Ρ Π³Π»ΠΈΠΊΠ΅ΠΌΠΈΠΈ, ΡΠ½ΠΈΠΆΠ΅Π½ΠΈΡ Π³Π»ΡΠΊΠΎΠ·ΡΡΠΈΠΈ, Π°Π»ΡΠ±ΡΠΌΠΈΠ½ΡΡΠΈΠΈ ΠΈ ΠΈΠ½Π΄Π΅ΠΊΡΠ° ΠΌΠ°ΡΡΡ ΡΠ΅Π»Π°, ΠΈ ΠΠ Ρ Π½ΠΎΡΠΌΠ°Π»ΠΈΠ·Π°ΡΠΈΠ΅ΠΉ ΡΠΈΡΡ ΠΠ.
7. ΠΡΠΈΠΌΠ΅Π½Π΅Π½ΠΈΠ΅ ΠΠΠ Π² ΠΊΠΎΠΌΠΏΠ»Π΅ΠΊΡΠ½ΠΎΠΉ ΡΠ΅ΡΠ°ΠΏΠΈΠΈ Π±ΠΎΠ»ΡΠ½ΡΡ Ρ ΡΠΎΡΠ΅ΡΠ°Π½ΠΈΠ΅ΠΌ Π₯Π‘Π ΠΈ Π‘Π 2 ΡΠΈΠΏΠ° ΠΎΠΊΠ°Π·Π°Π»ΠΎΡΡ Π°Π±ΡΠΎΠ»ΡΡΠ½ΠΎ Π±Π΅Π·ΠΎΠΏΠ°ΡΠ½ΡΠΌ: ΡΠ°ΠΊΠΆΠ΅ ΠΊΠ°ΠΊ ΠΏΡΠΈ Π»Π΅ΡΠ΅Π½ΠΈΠΈ ΠΠΠΠ€ ΡΠ½ΠΈΠΆΠ°Π»ΡΡ ΡΡΠΎΠ²Π΅Π½Ρ Π³Π»ΠΈΠΊΠ΅ΠΌΠΈΠΈ (Π½Π° 15,3%), ΠΈ Π°Π»ΡΠ±ΡΠΌΠΈΠ½ΡΡΠΈΠΈ (Ρ 67,8 Π΄ΠΎ 27,3%) ΠΈ Π½ΠΎΡΠΌΠ°Π»ΠΈΠ·ΠΎΠ²Π°Π»ΡΡ Π»ΠΈΠΏΠΈΠ΄Π½ΡΠΉ ΡΠΏΠ΅ΠΊΡΡ Π² Π²ΠΈΠ΄Π΅ Π΄ΠΎΡΡΠΎΠ²Π΅ΡΠ½ΠΎΠ³ΠΎ ΡΠ½ΠΈΠΆΠ΅Π½ΠΈΡ ΡΡΠΎΠ²Π½Ρ ΠΎΠ±ΡΠ΅Π³ΠΎ (Ρ 6,4 Π΄ΠΎ 5,9 ΠΌΠΌΠΎΠ»Ρ/Π») ΠΈ Ρ ΠΎΠ»Π΅ΡΡΠ΅ΡΠΈΠ½Π° ΠΠΠΠΠ (Π½Π° 11%) ΠΈ ΡΡΠΈΠ³Π»ΠΈΡΠ΅ΡΠΈΠ΄ΠΎΠ² (Π½Π° 13,6%), ΠΏΡΠΈ ΠΎΠ΄Π½ΠΎΠ²ΡΠ΅ΠΌΠ΅Π½Π½ΠΎΠΌ ΡΠ²Π΅Π»ΠΈΡΠ΅Π½ΠΈΠΈ Ρ ΠΎΠ»Π΅ΡΡΠ΅ΡΠΈΠ½Π° ΠΠΠΠ (Π½Π° 9,7%). Π’ΠΎ Π΅ΡΡΡ ΡΠ΅Π°Π»ΡΠ½ΡΡ ΠΏΡΠ΅ΠΏΡΡΡΡΠ²ΠΈΠΉ ΠΊ Π½Π°Π·Π½Π°ΡΠ΅Π½ΠΈΡ ΠΠΠ Π² ΠΊΠΎΠΌΠΏΠ»Π΅ΠΊΡΠ½ΠΎΠΌ Π»Π΅ΡΠ΅Π½ΠΈΠΈ Π₯Π‘Π, ΡΠΎΡΠ΅ΡΠ°ΡΡΠ΅ΠΉΡΡ Ρ Π‘Π 2 ΡΠΈΠΏΠ° Π½Π΅ ΠΈΠΌΠ΅Π΅ΡΡΡ.
8. ΠΡΠΏΠΎΠ»ΡΠ·ΠΎΠ²Π°Π½ΠΈΠ΅ Π² ΠΊΠΎΠΌΠ±ΠΈΠ½Π°ΡΠΈΠΈ ΠΠΠΠ€ Ρ ΠΠΠ Π΄Π»Ρ Π»Π΅ΡΠ΅Π½ΠΈΡ Π±ΠΎΠ»ΡΠ½ΡΡ Ρ ΡΠΎΡΠ΅ΡΠ°Π½ΠΈΠ΅ΠΌ Π₯Π‘Π ΠΈ Π‘Π 2 ΡΠΈΠΏΠ° Π½Π΅ ΠΏΠΎΠ·Π²ΠΎΠ»ΠΈΠ»ΠΎ Π΄ΠΎΠ±ΠΈΡΡΡΡ Π΄ΠΎΠΏΠΎΠ»Π½ΠΈΡΠ΅Π»ΡΠ½ΡΡ ΠΏΡΠ΅ΠΈΠΌΡΡΠ΅ΡΡΠ² Π² ΡΠ»ΡΡΡΠ΅Π½ΠΈΠΈ ΠΊΠ»ΠΈΠ½ΠΈΡΠ΅ΡΠΊΠΈΡ ΠΈ Π»Π°Π±ΠΎΡΠ°ΡΠΎΡΠ½ΡΡ ΠΏΠΎΠΊΠ°Π·Π°ΡΠ΅Π»Π΅ΠΉ, Π΄Π°ΠΆΠ΅ ΡΠ½ΠΈΠΆΠ΅Π½ΠΈΠ΅ Π§Π‘Π‘ ΠΈ ΠΠ, ΡΠ²Π»ΡΡΡΠΈΡ ΡΡ «Π·Π΅ΡΠΊΠ°Π»ΠΎΠΌ» ΡΡΠΏΠ΅ΡΠ½ΠΎΠ³ΠΎ ΠΏΡΠΈΠΌΠ΅Π½Π΅Π½ΠΈΡ ΠΠΠ Π±ΡΠ»ΠΎ ΠΎΠ΄ΠΈΠ½Π°ΠΊΠΎΠ²ΡΠΌ Π² ΠΏΠΎΠ΄Π³ΡΡΠΏΠΏΠ°Ρ Π±ΠΎΠ»ΡΠ½ΡΡ Ρ Π½Π°Π·Π½Π°ΡΠ΅Π½ΠΈΠ΅ΠΌ ΡΠΎΠ»ΡΠΊΠΎ ΠΠΠΠ€ ΠΈ ΠΊΠΎΠΌΠ±ΠΈΠ½Π°ΡΠΈΠΈ ΠΠΠΠ€ Ρ ΠΠΠ.
9. ΠΠ·ΠΌΠ΅Π½Π΅Π½ΠΈΡ ΡΠ΅Π½ΡΡΠ°Π»ΡΠ½ΠΎΠΉ Π³Π΅ΠΌΠΎΠ΄ΠΈΠ½Π°ΠΌΠΈΠΊΠΈ Π±ΡΠ»ΠΈ ΠΎΡΠΌΠ΅ΡΠ΅Π½Ρ Π² ΠΎΠ±Π΅ΠΈΡ Π³ΡΡΠΏΠΏΠ°Ρ Π»Π΅ΡΠ΅Π½ΠΈΡ ΠΈ ΠΏΡΠΈ ΠΏΡΠΈΠΌΠ΅Π½Π΅Π½ΠΈΠΈ ΠΠΠΠ€ ΠΈ ΠΈΡ ΠΊΠΎΠΌΠ±ΠΈΠ½Π°ΡΠΈΠΈ Ρ ΠΠΠ, ΠΏΡΠΈΡΠ΅ΠΌ Π² Π΄ΠΈΠ½Π°ΠΌΠΈΠΊΠ΅ ΡΠΈΡΡΠΎΠ»ΠΈΡΠ΅ΡΠΊΠΎΠΉ ΡΡΠ½ΠΊΡΠΈΠΈ ΡΠ°Π·Π»ΠΈΡΠΈΠΉ Π½Π΅ Π±ΡΠ»ΠΎ Π²ΡΡΠ²Π»Π΅Π½ΠΎ, ΠΈ Π»ΠΈΡΡ Π½ΠΎΡΠΌΠ°Π»ΠΈΠ·Π°ΡΠΈΡ Π΄ΠΈΠ°ΡΡΠΎΠ»ΠΈΡΠ΅ΡΠΊΠΎΠΉ ΡΡΠ½ΠΊΡΠΈΠΈ Π»Π΅Π²ΠΎΠ³ΠΎ ΠΆΠ΅Π»ΡΠ΄ΠΎΡΠΊΠ° Π΄ΠΎΡΡΠΈΠ³Π°Π»Π°ΡΡ ΡΠΎΠ»ΡΠΊΠΎ ΠΏΡΠΈ ΡΠΎΡΠ΅ΡΠ°Π½Π½ΠΎΠΌ ΠΏΡΠΈΠΌΠ΅Π½Π΅Π½ΠΈΠΈ ΠΠΠΠ€ ΠΈ ΠΠΠ, Ρ. Π΅ ΡΠΎΠ²ΠΌΠ΅ΡΡΠ½ΠΎΠ΅ ΠΏΡΠΈΠΌΠ΅Π½Π΅Π½ΠΈΠ΅ Π΄Π²ΡΡ Π½Π΅ΠΉΡΠΎΠ³ΡΠΌΠΎΡΠ°Π»ΡΠ½ΡΡ ΠΌΠΎΠ΄ΡΠ»ΡΡΠΎΡΠΎΠ² ΠΈΠΌΠ΅Π΅Ρ Π±ΠΎΠ»ΡΡΠΈΠΉ ΠΏΠΎΡΠ΅Π½ΡΠΈΠ°Π» Π² Π±Π»ΠΎΠΊΠ°Π΄Π΅ ΠΏΡΠΎΡΠ΅ΡΡΠΎΠ² ΡΠ΅ΠΌΠΎΠ΄Π΅Π»ΠΈΡΠΎΠ²Π°Π½ΠΈΡ ΠΈ Π·Π°ΠΌΠ΅Π΄Π»Π΅Π½ΠΈΠΈ ΠΏΡΠΎΠ³ΡΠ΅ΡΡΠΈΡΠΎΠ²Π°Π½ΠΈΡ Π±ΠΎΠ»Π΅Π·Π½ΠΈ.
10.ΠΠΎ Π΄Π°Π½Π½ΡΠΌ ΡΠ΅ΡΡΠΎΡΠΏΠ΅ΠΊΡΠΈΠ²Π½ΠΎΠ³ΠΎ Π°Π½Π°Π»ΠΈΠ·Π° ΠΈΠΌΠ΅Π»Π°ΡΡ ΡΠ΅Π½Π΄Π΅Π½ΡΠΈΡ ΠΊ ΡΠ²Π΅Π»ΠΈΡΠ΅Π½ΠΈΡ ΡΠΈΡΠΊΠ° ΡΠΌΠ΅ΡΡΠΈ Π±ΠΎΠ»ΡΠ½ΡΡ Ρ Π₯Π‘Π ΠΈ Π‘Π 2 ΡΠΈΠΏΠ° Π² ΡΡΠ°Π²Π½Π΅Π½ΠΈΠΈ Ρ Π±ΠΎΠ»ΡΠ½ΡΠΌΠΈ Ρ Π₯Π‘Π (Π½Π° 22%), ΠΏΡΠΈ ΡΡΠΎΠΌ Π½Π°Π»ΠΈΡΠΈΠ΅ Π‘Π 2 ΡΠΈΠΏΠ° Π΄ΠΎΡΡΠΎΠ²Π΅ΡΠ½ΠΎ ΡΡ ΡΠ΄ΡΠ°Π΅Ρ ΠΏΡΠΎΠ³Π½ΠΎΠ· Ρ ΠΆΠ΅Π½ΡΠΈΠ½ (Π½Π° 45%), Ρ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² Ρ ΠΎΡΠ½ΠΎΡΠΈΡΠ΅Π»ΡΠ½ΠΎ ΡΠΎΡ ΡΠ°Π½Π½ΠΎΠΉ Π€Π ΠΠ (Π½Π° 46%) ΠΈ ΠΏΡΠΈ ΡΠΎΡ ΡΠ°Π½Π½ΠΎΠΌ Π‘ΠΠ (Π½Π° 42%). ΠΡΠΈ Π½ΠΈΠ·ΠΊΠΎΠΉ Π€Π ΠΈ Π³ΠΈΠΏΠΎΡΠΎΠ½ΠΈΠΈ ΡΡΠΆΠ΅ΡΡΡ ΠΏΡΠΎΠ³Π½ΠΎΠ·Π° ΠΎΠΏΡΠ΅Π΄Π΅Π»ΡΠ΅ΡΡΡ ΡΠ°ΠΌΠΎΠΉ Π₯Π‘Π, Π° Π½Π΅ ΠΏΡΠΈΡΠΎΠ΅Π΄ΠΈΠ½ΠΈΠ²ΡΠΈΠΌΡΡ Π‘Π 2 ΡΠΈΠΏΠ°.
11 .ΠΡΠΈ ΠΏΡΠΎΡΠΏΠ΅ΠΊΡΠΈΠ²Π½ΠΎΠΌ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΠΈ ΡΠ°ΡΡΠΎΡΠ° ΡΠ΅ΡΠ΄Π΅ΡΠ½ΠΎ — ΡΠΎΡΡΠ΄ΠΈΡΡΡΡ ΠΎΡΠ»ΠΎΠΆΠ½Π΅Π½ΠΈΠΉ (ΠΠΠ + ΠΈΠ½ΡΡΠ»ΡΡΡ + ΠΎΠ±ΠΎΡΡΡΠ΅Π½ΠΈΠ΅ Π₯Π‘Π + Π½ΠΎΠ²Π°Ρ ΠΠΠ£ + ΡΡΠ΅Π½ΠΎΠΊΠ°ΡΠ΄ΠΈΡ) Π² Π³ΡΡΠΏΠΏΠ΅ Π±ΠΎΠ»ΡΠ½ΡΡ Ρ ΡΠΎΡΠ΅ΡΠ°Π½ΠΈΠ΅ΠΌ Π₯Π‘Π ΠΈ Π‘Π 2 ΡΠΈΠΏΠ° Π±ΡΠ»Π° Π΄ΠΎΡΡΠΎΠ²Π΅ΡΠ½ΠΎ Π²ΡΡΠ΅, ΡΠ΅ΠΌ ΠΏΡΠΈ «ΠΈΠ·ΠΎΠ»ΠΈΡΠΎΠ²Π°Π½Π½ΠΎΠΉ» Π₯Π‘Π (ΠΏΡΠΈ Π‘Π 2 ΡΠΈΠΏΠ° Π΄Π»ΠΈΡΠ΅Π»ΡΠ½ΠΎΡΡΡΡ Π±ΠΎΠ»Π΅Π΅ 10 Π»Π΅Ρ — 63,5% ΠΏΡΠΎΡΠΈΠ² 37,9%). ΠΡΠΈ ΠΎΠ΄Π½ΠΎΡΠ°ΠΊΡΠΎΡΠ½ΠΎΠΌ Π°Π½Π°Π»ΠΈΠ·Π΅, ΡΠ°ΠΊΡΠΎΡΠ°ΠΌΠΈ, Π΄ΠΎΡΡΠΎΠ²Π΅ΡΠ½ΠΎ ΠΎΠΏΡΠ΅Π΄Π΅Π»ΡΡΡΠΈΠΌΠΈ ΡΠ°Π·Π²ΠΈΡΠΈΠ΅ ΡΠ΅ΡΠ΄Π΅ΡΠ½ΠΎΡΠΎΡΡΠ΄ΠΈΡΡΡΡ ΠΎΡΠ»ΠΎΠΆΠ½Π΅Π½ΠΈΠΉ ΡΠ²Π»ΡΠ»ΠΈΡΡ: Π²ΠΎΠ·ΡΠ°ΡΡ, Π΄Π»ΠΈΡΠ΅Π»ΡΠ½ΠΎΡΡΡ Π΄ΠΈΠ°Π±Π΅ΡΠ°, Π½Π°Π»ΠΈΡΠΈΠ΅ ΠΠ Π² Π°Π½Π°ΠΌΠ½Π΅Π·Π΅, Π±ΠΎΠ»ΡΡΠΈΠΉ ΠΈΠ½Π΄Π΅ΠΊΡ ΠΌΠ°ΡΡΡ ΡΠ΅Π»Π°, ΡΠ²Π΅Π»ΠΈΡΠ΅Π½ΠΈΠ΅ ΡΡΠΈΠ³Π»ΠΈΡΠ΅ΡΠΈΠ΄ΠΎΠ², Π΄ΠΈΠ°ΡΡΠΎΠ»ΠΈΡΠ΅ΡΠΊΠ°Ρ Π΄ΠΈΡΡΡΠ½ΠΊΡΠΈΡ, Π° ΡΠ°ΠΊΠΆΠ΅ Π½Π°Π»ΠΈΡΠΈΠ΅ ΠΌΠΈΠΊΡΠΎΠ°Π»ΡΠ±ΡΠΌΠΈΠ½ΡΡΠΈΠΈ.
12.ΠΠ΅ΡΠ΅Π½ΠΈΠ΅ ΠΈΠ½Π³ΠΈΠ±ΠΈΡΠΎΡΠ°ΠΌΠΈ ΠΠΠ€ ΠΈΠ·ΠΎΠ»ΠΈΡΠΎΠ²Π°Π½Π½ΠΎ ΠΈΠ»ΠΈ Π² ΡΠΎΡΠ΅ΡΠ°Π½ΠΈΠΈ Ρ |3-Π±Π»ΠΎΠΊΠ°ΡΠΎΡΠ°ΠΌΠΈ Π½Π΅ ΠΏΠΎΠ·Π²ΠΎΠ»ΡΠ΅Ρ Π΄ΠΎΡΡΠΎΠ²Π΅ΡΠ½ΠΎ ΡΠ½ΠΈΠ·ΠΈΡΡ ΡΠΈΡΠ»ΠΎ ΡΠ΅ΡΠ΄Π΅ΡΠ½ΠΎ — ΡΠΎΡΡΠ΄ΠΈΡΡΡΡ ΠΎΡΠ»ΠΎΠΆΠ½Π΅Π½ΠΈΠΉ ΠΈ ΡΡΠΎΠ²Π½ΡΡΡ ΡΠΈΡΠΊ Π±ΠΎΠ»ΡΠ½ΡΡ Ρ ΡΠΎΡΠ΅ΡΠ°Π½ΠΈΠ΅ΠΌ Π₯Π‘Π + Π‘Π 2 ΡΠΈΠΏΠ° Ρ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠ°ΠΌΠΈ Ρ ΠΈΠ·ΠΎΠ»ΠΈΡΠΎΠ²Π°Π½Π½ΠΎΠΉ Π₯Π‘Π. ΠΡΠΈ ΠΊΠΎΠΌΠΏΠ»Π΅ΠΊΡΠ½ΠΎΠΉ ΡΠ΅ΡΠ°ΠΏΠΈΠΈ ΠΈΠ½Π³ΠΈΠ±ΠΈΡΠΎΡΠ°ΠΌΠΈ ΠΠΠ€ ΠΈ Ρ-Π±Π»ΠΎΠΊΠ°ΡΠΎΡΠ°ΠΌΠΈ Π±ΠΎΠ»ΡΠ½ΡΡ Ρ Π₯Π‘Π ΠΈ Π‘Π 2 ΡΠΈΠΏΠ° ΠΈΠΌΠ΅Π΅ΡΡΡ ΡΠ΅Π½Π΄Π΅Π½ΡΠΈΡ ΠΊ ΠΌΠ΅Π½ΡΡΠ΅ΠΌΡ Π²ΠΎΠ·Π½ΠΈΠΊΠ½ΠΎΠ²Π΅Π½ΠΈΡ ΡΠ΅ΡΠ΄Π΅ΡΠ½ΠΎ — ΡΠΎΡΡΠ΄ΠΈΡΡΡΡ ΠΎΡΠ»ΠΎΠΆΠ½Π΅Π½ΠΈΠΉ, ΠΏΡΠ΅ΠΆΠ΄Π΅ Π²ΡΠ΅Π³ΠΎ, ΡΠ»ΡΡΠ°Π΅Π² ΠΎΠ±ΠΎΡΡΡΠ΅Π½ΠΈΡ Π₯Π‘Π. ΠΠΈΠ΄ΠΈΠΌΠΎ Π΄Π»Ρ Π΄ΠΎΡΡΠΎΠ²Π΅ΡΠ½ΠΎΠ³ΠΎ ΡΠ½ΠΈΠΆΠ΅Π½ΠΈΡ ΡΠΈΡΠΊΠ° Π½Π΅ΠΎΠ±Ρ ΠΎΠ΄ΠΈΠΌΠΎ Π°Π³ΡΠ΅ΡΡΠΈΠ²Π½ΠΎΠ΅ Π»Π΅ΡΠ΅Π½ΠΈΠ΅ Π½Π΅ ΡΠΎΠ»ΡΠΊΠΎ Π₯Π‘Π, Π½ΠΎ ΠΈ Π²ΡΠΎΡΠΎΠ³ΠΎ ΠΊΠΎΠΌΠΏΠΎΠ½Π΅Π½ΡΠ°Π‘Π 2 ΡΠΈΠΏΠ°.
ΠΠ ΠΠΠ’ΠΠ§ΠΠ‘ΠΠΠ Π ΠΠΠΠΠΠΠΠΠ¦ΠΠ.
1. Π£ΡΠΈΡΡΠ²Π°Ρ, ΡΡΠΎ ΠΏΡΠΈΡΠΎΠ΅Π΄ΠΈΠ½Π΅Π½ΠΈΠ΅ Π‘Π 2 ΡΠΈΠΏΠ° ΡΠ΅ΡΡΠ΅Π·Π½ΠΎ ΠΎΡΠ»ΠΎΠΆΠ½ΡΠ΅Ρ ΡΠ΅ΡΠ΅Π½ΠΈΠ΅ Π₯Π‘Π ΠΈ ΡΡΠ΅Π±ΡΠ΅Ρ ΡΠΏΠ΅ΡΠΈΠ°Π»ΡΠ½ΠΎΠ³ΠΎ Π²ΠΎΠ·Π΄Π΅ΠΉΡΡΠ²ΠΈΡ, Π½Π΅ΠΎΠ±Ρ ΠΎΠ΄ΠΈΠΌΠΎ ΡΠ΅ΠΊΠΎΠΌΠ΅Π½Π΄ΠΎΠ²Π°ΡΡ Π²ΡΠ΅ΠΌ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠ°ΠΌ Ρ Π΄Π΅ΠΊΠΎΠΌΠΏΠ΅Π½ΡΠ°ΡΠΈΠ΅ΠΉ ΠΏΡΠΎΠ²Π΅Π΄Π΅Π½ΠΈΠ΅ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΠΉ, Π½Π°ΠΏΡΠ°Π²Π»Π΅Π½Π½ΡΡ Π½Π° ΡΠ²ΠΎΠ΅Π²ΡΠ΅ΠΌΠ΅Π½Π½ΠΎΠ΅ Π²ΡΡΠ²Π»Π΅Π½ΠΈΠ΅ Π‘Π 2 ΡΠΈΠΏΠ° (ΠΊΠΎΠ½ΡΡΠΎΠ»Ρ Π·Π° ΡΡΠΎΠ²Π½Π΅ΠΌ Π³Π»ΡΠΊΠΎΠ·Ρ Π½Π°ΡΠΎΡΠ°ΠΊ, ΠΏΡΠΎΠ±Ρ Π½Π° ΡΠΎΠ»Π΅ΡΠ°Π½ΡΠ½ΠΎΡΡΡ ΠΊ Π³Π»ΡΠΊΠΎΠ·Π΅, ΡΡΠΎΠ²Π΅Π½Ρ Π³Π»ΡΠΊΠΎΠ·ΡΡΠΈΠΈ).
2. ΠΠ»Ρ Π±ΠΎΠ»ΡΠ½ΡΡ Ρ ΡΠΎΡΠ΅ΡΠ°Π½ΠΈΠ΅ΠΌ Π₯Π‘Π ΠΈ Π‘Π 2 ΡΠΈΠΏΠ° Π½Π΅ΠΎΠ±Ρ ΠΎΠ΄ΠΈΠΌΡΠΌ ΡΠ²Π»ΡΠ΅ΡΡΡ ΡΡΠ°ΡΠ΅Π»ΡΠ½ΡΠΉ ΠΊΠΎΠ½ΡΡΠΎΠ»Ρ Π·Π° ΡΡΠ½ΠΊΡΠΈΠ΅ΠΉ ΠΏΠΎΡΠ΅ΠΊ (ΠΎΠΏΡΠ΅Π΄Π΅Π»Π΅Π½ΠΈΠ΅ ΡΡΠΎΠ²Π½Ρ ΠΊΡΠ΅Π°ΡΠΈΠ½ΠΈ-Π½Π° ΠΈ ΠΌΠΈΠΊΡΠΎΠ°Π»ΡΠ±ΡΠΌΠΈΠ½ΡΡΠΈΠΈ, Π³Π»ΡΠΊΠΎΠ·ΡΡΠΈΠΈ), ΡΡΠΎ ΠΏΠΎΠ·Π²ΠΎΠ»ΠΈΡ ΡΠ²ΠΎΠ΅Π²ΡΠ΅ΠΌΠ΅Π½Π½ΠΎ ΠΏΡΠΎΠ²ΠΎΠ΄ΠΈΡΡ ΠΊΠΎΡΡΠ΅ΠΊΡΠΈΡ ΡΡΠΈΡ Π½Π°ΡΡΡΠ΅Π½ΠΈΠΉ.
3. ΠΠ΅ΡΠΌΠΎΡΡΡ Π½Π° Π½Π°Π»ΠΈΡΠΈΠ΅ Π²ΡΡΠ°ΠΆΠ΅Π½Π½ΠΎΠΉ Π΄Π΅ΠΊΠΎΠΌΠΏΠ΅Π½ΡΠ°ΡΠΈΠΈ ΠΈ ΡΡ ΡΠ΄ΡΠ΅Π½ΠΈΠ΅ ΡΡΠ½ΠΊΡΠΈΠΈ ΠΏΠ΅ΡΠ΅Π½ΠΈ, Π±ΠΎΠ»ΡΠ½ΡΠΌ Ρ ΡΠΎΡΠ΅ΡΠ°Π½ΠΈΠ΅ΠΌ Π‘Π 2 ΡΠΈΠΏΠ° ΠΈ Π₯Π‘Π Π΄ΠΎΠ»ΠΆΠ½ΠΎ ΠΏΡΠΎΠ²ΠΎΠ΄ΠΈΡΡΡΡ ΡΠ΅Π³ΡΠ»ΡΡΠ½ΠΎΠ΅ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΠ΅ Π»ΠΈΠΏΠΈΠ΄Π½ΠΎΠ³ΠΎ ΠΏΡΠΎΡΠΈΠ»Ρ, ΡΡΠΎ ΠΏΠΎΠ·Π²ΠΎΠ»ΠΈΡ ΡΠ²ΠΎΠ΅Π²ΡΠ΅ΠΌΠ΅Π½Π½ΠΎ ΠΏΡΠΈΡΠΎΠ΅Π΄ΠΈΠ½ΡΡΡ Π³ΠΈΠΏΠΎΠ»ΠΈΠΏΠΈΠ΄Π΅ΠΌΠΈΡΠ΅ΡΠΊΡΡ ΡΠ΅ΡΠ°ΠΏΠΈΡ.
4. ΠΠ°ΠΊΡΠΈΠΌΠ°Π»ΡΠ½ΠΎΠ΅ Π²Π½ΠΈΠΌΠ°Π½ΠΈΠ΅ Π΄ΠΎΠ»ΠΆΠ½ΠΎ ΡΠ΄Π΅Π»ΡΡΡΡΡ ΠΆΠ΅Π½ΡΠΈΠ½Π°ΠΌ ΠΈ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠ°ΠΌ Ρ ΡΠΎΡ ΡΠ°Π½Π½ΠΎΠΉ ΡΠΎΠΊΡΠ°ΡΠΈΡΠ΅Π»ΡΠ½ΠΎΠΉ ΡΡΠ½ΠΊΡΠΈΠ΅ΠΉ ΠΠ (Π€Π > 38%) ΠΈ ΡΠΎΡ ΡΠ°Π½Π΅Π½Π½ΡΠΌ ΡΡΠΎΠ²Π½Π΅ΠΌ ΡΠΈΡΡΠΎΠ»ΠΈΡΠ΅ΡΠΊΠΎΠ³ΠΎ ΠΠ (> 120 ΠΌΠΌ.ΡΡ.ΡΡ), Ρ.ΠΊ. Ρ ΡΡΠΈΡ ΠΊΠ°ΡΠ΅Π³ΠΎΡΠΈΠΉ Π±ΠΎΠ»ΡΠ½ΡΡ ΠΈΠΌΠ΅Π½Π½ΠΎ ΡΠ΅ΡΠ΅Π½ΠΈΠ΅ Π‘Π 2 ΡΠΈΠΏΠ° ΠΌΠ°ΠΊΡΠΈΠΌΠ°Π»ΡΠ½ΠΎ ΠΎΠΏΡΠ΅Π΄Π΅Π»ΡΠ΅Ρ ΡΠΈΡΠ»ΠΎ ΠΎΡΠ»ΠΎΠΆΠ½Π΅Π½ΠΈΠΉ ΠΈ ΠΏΡΠΎΠ³Π½ΠΎΠ· Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π½ΠΈΡ. ΠΡΠΈ Π³ΡΡΠΏΠΏΡ Π±ΠΎΠ»ΡΠ½ΡΡ ΡΡΠ΅Π±ΡΡΡ ΡΠΎΠ²ΠΌΠ΅ΡΡΠ½ΠΎΠ³ΠΎ ΠΊΠΎΠ½ΡΡΠΎΠ»Ρ ΠΊΠ°ΡΠ΄ΠΈΠΎΠ»ΠΎΠ³ΠΎΠ² ΠΈ ΡΠ½Π΄ΠΎΠΊΡΠΈΠ½ΠΎΠ»ΠΎΠ³ΠΎΠ².
5. ΠΠ΅ΡΠ΅Π½ΠΈΠ΅ Π±ΠΎΠ»ΡΠ½ΡΡ Ρ ΡΠΎΡΠ΅ΡΠ°Π½ΠΈΠ΅ΠΌ Π‘Π 2 ΡΠΈΠΏΠ° ΠΈ Π₯Π‘Π Π΄ΠΎΠ»ΠΆΠ½ΠΎ Π²ΠΊΠ»ΡΡΠ°ΡΡ ΠΏΡΠΈΠΌΠ΅Π½Π΅Π½ΠΈΠ΅ ΠΠΠΠ€, ΠΊΠΎΡΠΎΡΡΠ΅ ΠΏΠΎΠ·Π²ΠΎΠ»ΡΡΡ ΡΠΌΠ΅Π½ΡΡΠΈΡΡ Π²ΡΡΠ°ΠΆΠ΅Π½Π½ΠΎΡΡΡ Π΄Π΅ΠΊΠΎΠΌΠΏΠ΅Π½ΡΠ°ΡΠΈΠΈ, ΠΎΠ΄Π½ΠΎΠ²ΡΠ΅ΠΌΠ΅Π½Π½ΠΎ Π½ΠΎΡΠΌΠ°Π»ΠΈΠ·ΠΎΠ²Π°ΡΡ ΠΠ, Π·Π°ΡΠΈΡΠΈΡΡ ΠΏΠΎΡΠΊΠΈ ΠΈ ΡΠ»ΡΡΡΠΈΡΡ ΡΠ΅ΡΠ΅Π½ΠΈΠ΅ Π‘Π 2 ΡΠΈΠΏΠ° ΠΈ ΠΎΠ±Π»Π΅Π³ΡΠΈΡΡ ΠΊΠΎΠ½ΡΡΠΎΠ»Ρ Π·Π° ΡΡΠΎΠ²Π½Π΅ΠΌ Π³Π»ΠΈΠΊΠ΅ΠΌΠΈΠΈ.
6. ΠΡΠΈΠΌΠ΅Π½Π΅Π½ΠΈΠ΅ ΠΠΠ Ρ Π±ΠΎΠ»ΡΠ½ΡΡ Ρ Π₯Π‘Π ΠΈ Π‘Π 2 ΡΠΈΠΏΠ° ΠΎΠΊΠ°Π·Π°Π»ΠΎΡΡ «ΠΊΡΠ°ΠΉΠ½Π΅ ΡΡΡΠ΅ΠΊΡΠΈΠ²Π½ΡΠΌ ΠΈ Π°Π±ΡΠΎΠ»ΡΡΠ½ΠΎ Π±Π΅Π·ΠΎΠΏΠ°ΡΠ½ΡΠΌ, Π½Π΅ ΡΡΡΠ³ΡΠ±Π»ΡΡΡΠΈΠΌ ΡΠ΅ΡΠ΅Π½ΠΈΡ Π‘Π 2 ΡΠΈΠΏΠ°.
7. Π‘ΠΎΡΠ΅ΡΠ°Π½Π½ΠΎΠ΅ ΠΏΡΠΈΠΌΠ΅Π½Π΅Π½ΠΈΠ΅ ΠΠΠΠ€ ΠΈ ΠΠΠ ΠΏΠΎΠ·Π²ΠΎΠ»ΡΠ΅Ρ ΠΌΠ°ΠΊΡΠΈΠΌΠ°Π»ΡΠ½ΠΎ ΡΠ½ΠΈΠΆΠ°ΡΡ ΡΠΈΡΠΊ ΠΎΡΠ»ΠΎΠΆΠ½Π΅Π½ΠΈΠΉ, ΡΠ»ΡΡΡΠ°ΡΡ ΡΠ΅ΡΠ΅Π½ΠΈΠ΅ Π₯Π‘Π ΠΈ ΠΌΠ°ΠΊΡΠΈΠΌΠ°Π»ΡΠ½ΠΎ Π±Π»ΠΎΠΊΠΈΡΠΎΠ²Π°ΡΡ ΠΏΡΠΎΡΠ΅ΡΡΡ ΡΠ΅ΠΌΠΎΠ΄Π΅Π»ΠΈΡΠΎΠ²Π°Π½ΠΈΡ ΠΠ, ΡΡΠΎ Π΄Π΅Π»Π°Π΅Ρ ΡΠ°ΠΊΠΎΠΉ ΡΠ΅ΠΆΠΈΠΌ ΡΠ΅ΡΠ°ΠΏΠΈΠΈ ΠΏΠΎΠΊΠ°Π·Π°Π½Π½ΡΠΌ Π²ΡΠ΅ΠΌ Π±ΠΎΠ»ΡΠ½ΡΠΌ Ρ ΡΠΎΡΠ΅ΡΠ°Π½ΠΈΠ΅ΠΌ Π₯Π‘Π ΠΈ Π‘Π 2 ΡΠΈΠΏΠ°, Π½Π΅ ΠΈΠΌΠ΅ΡΡΠΈΠΌ ΡΠΏΠ΅ΡΠΈΠ°Π»ΡΠ½ΡΡ ΠΈΠ½Π΄ΠΈΠ²ΠΈΠ΄ΡΠ°Π»ΡΠ½ΡΡ ΠΏΡΠΎΡΠΈΠ²ΠΎΠΏΠΎΠΊΠ°Π·Π°Π½ΠΈΠΉ.
8. Π£ΡΠΈΡΡΠ²Π°Ρ, ΡΡΠΎ Π΄Π°ΠΆΠ΅ ΠΏΡΠΈ ΠΊΠΎΠΌΠΏΠ»Π΅ΠΊΡΠ½ΠΎΠΉ ΡΠ΅ΡΠ°ΠΏΠΈΠΈ ΠΠΠΠ€ Ρ ΠΠΠ ΡΠΈΡΠΊ ΡΠ΅ΡΠ΄Π΅ΡΠ½ΠΎ — ΡΠΎΡΡΠ΄ΠΈΡΡΡΡ ΠΎΡΠ»ΠΎΠΆΠ½Π΅Π½ΠΈΠΉ Ρ Π±ΠΎΠ»ΡΠ½ΡΡ Ρ Π₯Π‘Π ΠΈ Π‘Π 2 ΡΠΈΠΏΠ° ΠΎΡΡΠ°Π΅ΡΡΡ Π΄ΠΎΡΡΠΎΠ²Π΅ΡΠ½ΠΎ ΠΏΠΎΠ²ΡΡΠ΅Π½Π½ΡΠΌ, Π²Π°ΠΆΠ½ΡΠΌ ΠΊΠΎΠΌΠΏΠΎΠ½Π΅Π½ΡΠΎΠΌ ΡΠ΅ΡΠ°ΠΏΠΈΠΈ, ΠΏΠΎΠ·Π²ΠΎΠ»ΡΡΡΠ΅ΠΉ Π΄ΠΎΠ±ΠΈΠ²Π°ΡΡΡΡ ΡΠ½ΠΈΠΆΠ΅Π½ΠΈΡ ΡΠΈΡΠΊΠ° ΡΠ΅ΡΠ΄Π΅ΡΠ½ΠΎ-ΡΠΎΡΡΠ΄ΠΈΡΡΡΡ ΠΎΡΠ»ΠΎΠΆΠ½Π΅Π½ΠΈΠΉ Π΄ΠΎΠ»ΠΆΠ½Π° Π±ΡΡΡ Π°Π³ΡΠ΅ΡΡΠΈΠ²Π½Π°Ρ Π³ΠΈΠΏΠΎΠ³Π»ΠΈΠΊΠ΅ΠΌΠΈΡΠ΅ΡΠΊΠ°Ρ ΡΠ΅ΡΠ°ΠΏΠΈΡ.
Π‘ΠΏΠΈΡΠΎΠΊ Π»ΠΈΡΠ΅ΡΠ°ΡΡΡΡ
- Abaci A., Oguzhan A., Kahraman S., et al. Effects of the diabetes mellitus on formation of coronary collateral vessels. Circulation 1999−99:2239—42.
- Akbari C., Saouaf R., Barnhill D., et al Endothelium-dependent vasodilation is impaired in both microcirculation and macrocirculation during acute hyperglycemia. J Vase Surg 1998−28:687−94.
- Akella A., Sonnenblick E., Gulati J. Alterations in myocardial contractile proteins in diabetes mellitus. Coron Artery Dis 1996−7:124—32.
- Almbrand Π., Johannesson Π., Sjostrand K., et al. Costs of improved survival among diabetics with myocardial infarction: Experiences from the DIGAMI study. Eur Heart J 1998−19(Suppl):241.
- Alio S., Lincoln Π’., Wilson G., et al. Non-insulin-dependent diabetes-induced defects in cardiac cellular calcium regulation. Am J Physiol 1991 -260:C1165—C71.
- Amato L., Paolisso G., Cacciatore F., et al. on behalf of the osservatorio geriatrico regione campania group. Congestive heart failure predicts the development of non-insulin dependent diabetes mellitus in the elderly. Diabetes Metab 1997−23:213−8.
- Ambepityia G., Kopelman P., Ingram D., et al. Exertional myocardial ischemia in diabetes: A quantitative analysis of anginal perceptual threshold and the influence of autonomic function. J Am Coll Cardiol 1990- 15:72—7.
- American Diabetic Association: Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 1997−20:1183—97.
- Aronson D., Bloomgarden Z., Rayfield E. Potential mechanisms promoting restenosis in diabetic patients. J Am Coll Cardiol 1996−27:528—35.
- Aspirin effects on mortality and morbidity in patients with diabetes mellitus. Early Treatment Diabetic Retinopathy Study report 14. ETDRS Investigators. JAMA 1992−268:1292−1300.
- Aspirin therapy in diabetes. American Diabetes Association. Diabetes Care 1997−20:1772−3.
- A study of the effects of hypoglycaemia agents on vascular complications in patients with adults-onset diabetes. VI. Supplementary report on nonfatal events in patients treated with tolbutamide. Diabetes 1976−25:1129—53.
- Avendano G., Agarwal R., Bashey R., et al. Effects of glucose intolerance on myocardial function and collagen-linked glycation. Diabetes 1999−48:1443—7.
- Balletshofer B., Ritting K., Enderle M., et al. Endothelial dysfunction is detectable in young normotensive first-degree relatives of subjects with type 2 diabetes in association with insulin resistance. Circulation 2000- 101:1780—4.
- BARI Investigators. Influance of diabetes on 5-year mortality and morbidity in randomised trial comparing CABG and PTCA in patients with multivessel disease: The Bypass Angioplasty Revascularisation Investigation (BARI). Circulation 1997−96:1761−9.
- Barrett-Connor E., Cohn B., Wingard D., et al. Why is diabetes mellitus a stronger risk factor for fatal ischemic heart disease in women than in men? The Rancho Bernardo Study. JAMA 1991−265:627−31.
- Baim D., Diver D., Feit F., et al. Coronary angioplasty performed within the Thrombolysis in Myocardial Infarction II study. Circulation 1992−85:93—105.
- Barzilay J., Kronmal R., Bittner V., et al. Coronary artery disease and coronary artery bypass grafting in diabetic patients aged >65 years (Report from the coronary artery surgery study CASS. registry). Am J Cardiol 1994−74:334—9.
- Baynes J., Thorpe S. Role of oxidative stress in diabetic complications: A new perspective on an old paradigm. Diabetes 1999−48:1—9.
- Bellodi G., Manicardi V., Malavasi V., et al Hyperglycaemia and prognosis of acute myocardial infarction in patients without diabetes mellitus. Am J Cardiol 1989−64:885−8.
- Berg T., Snorgaard O., Faber J., et al. Serum levels of advanced glycation end products are associated with left ventricular diastolic function in patients with type 1 diabetes. Diabetes Care 1999−22:1186—90.
- Bernardi L., Ricordi L., Lazzari P., et al. Impaired circadian modulation of sym-pathovagal activity in diabetes. A possible explanation for altered temporal onset of cardiovascular disease. Circulation 1992−86:1443—52.
- Bersin R., Wolfe C., Kwasman M., et al. Improved hemodynamic function and mechanical efficiency in congestive heart failure with sodium dichloroacetate. J Am Coll Cardiol 1994−23:1617−24.
- Bierman E. George Lyman Duff Memorial Lecture. Atherogenesis in diabetes. Ar-terioscler Thromb 1992- 12:647—56.
- Bijlstra P., Lutterman J., Russel F.} et al. Interaction of sulphonylurea derivatives with vascular ATR-sensitive potassium channels in humans. Diabetologia 1996−39:1083−90.
- Binkley P., Haas G., Starling R., et al. Sustained augmentation of parasympathetic tone with angiotensin-converting-enzyme inhibition in congestive heart failure. J Am Coll Cardiol 1993−21:655−61.
- Boger R., Bode-Boger S., Szuba A., et al. Asymmetric dimethylarginine (ADMA): A novel risk factor for endothelial dysfunction: Its role in hypercholesterolemia. Circulation 1998−98:1842−7.
- Bonora E., Kiechl S., Willeit J., et al. Prevalence of insulin resistance in metabolic desorders: The Bruneck Study. Diabetes 1998−47:1643−9.
- Brady P. Terzic A. The sulfonylurea controversy: More questions from the heart. J Am Coll Cardiol 1998−31:950—6.
- Bristow M., Gilbert E., Abraham W., et al. effect of carvedilol on LV function and mortality in diabetic versus non-diabetic patients with ischemic and nonischemic dilated cardiomyopathy. Circulation 1996−84(Suppl):AI:664.
- Brownlee M. Negative consequences of glycation. Metabolism 2000−49:9—13.
- Bucala R., Makita Z., Koschinsky T., et al Lipid advanced glycosylation: Pathway for lipid oxidation in vivo. Proc Natl Acad Sci USA 1993−90:6434—8.
- Burger A., Weinrauch L., D’Elia J., et al. Effect of glycemic control on heart rate variability in type I diabetic patients with cardiac autonomic neuropathy. Am J Cardiol 1999−84:687−91.
- Burgos L., Ebert T., Assidao C., et al. Increased intraoperative cardiovascular morbidity in diabetics with autonomic neuropathy. Anesthesiology 1989−970:591−7.
- Capes S., Hunt D., Malmberg K., et al. Stress hyperglycaemia and increased risk of death after acute myocardial infarction in patients with and without diabetes: A systematic overview. Lancet 2000−355:773—8.
- Carrozza J., Kuntz R., Fishman R., et al. Restenosis after arterial injury caused by coronary stenting in patients with diabetes mellitus. Ann Intern Med 1993−118:344−9.
- Celentano A., Vaccaro O., Tammaro P., et al. Early abnormalities of cardiac function in non-insulin-dependent diabetes mellitus and impaired glucose tolerance. Am J Cardiol 1995−76:1173—6.
- Chae C., Glynn R., Manson J., et al. Diabetes predicts congestive heart failure risk in the elderly. Circulation 1998−98(Suppl I):721.
- Chen J., Marciniak T., Radford M., et al. Beta-blocker therapy for secondary prevention of myocardial infarction in elderly diabetic patients. Results from the National Cooperative Cardiovascular Project. Am Coll Cardiol 1999−34:1388—94.
- Clark C., Perry R. Type 2 diabetes and macro cascular disease. Epidemiology and etiology. Am Heart J1999- 17:7—11.
- Cleveland J. Jr, Meldrum D., Cain B., et al. Oral sulfonylurea hypoglycaemic agents prevent ischemic preconditioning in human myocardium. Two paradoxes revisited. Circulation 1997−96:29—32.
- Cohn J., Johnson G., Ziesche S., et al. A comparison of enalapril with hydra-lazine-isosorbide dinitrate in the treatment of congestive heart failure. N Engl I Med 1991−325:303−10.
- Cole W., McPherson C., Sontag D. ATR-regulated K+ channels protect the myocardium against ischemia/reperfusion damage. Cir Res 1991 -69:571—81.
- Colwell J. Aspirin therapy in diabetes. Diabetes Care 1997−20:1767—71-.
- Comparison of coronary bypass surgery with angioplasty in patients with mul-tivessel disease. The Bypass Angioplasty Revascularisation Investigation (BAR!) Investigators. N Engl I Med 1996−335:217−25.
- Consensus development conference on the diagnosis of coronary heart disease in people with diabetes: 10—11 February 1998, Miami, Florida. American-Diabetes Association. Diabetes Care 1998−21:1551—9.
- CONSENSUS trial study group. Effect of enalapril on mortality in severe congestive heart failure. N Engl I Med 1987−316:1429−35.
- Cooke J. Does ADMA cause endothelial dysfunction? Arterioscler Thromb Vase Biol, in press.
- Cooper M., Johnston C. Optimizing treatment of hypertension in patients with diabetes. JAMA 2000−283:3177—9.
- Correa S., Schaefer S. Blockade of K (ATR) channels with glibenclamide does not abolish preconditioning during demand ischemia. Am J Cardiol 1997−79:75—8.
- Coughlin S., Neaton J., Sengupta A., et al. Predictors of mortality from idiopathic dilated cardiomyopathy in 356,222 men screened for the Multiple Risk Factor Intervention Trial. Am J Epidemiol 1994- 139:166—72.
- Coughlin S., Pearle D., Baughman K., et al. Diabetes mellitus and risk of idiopathic dilated cardiomyopathy. The Washington, DC Dilated Cardiomyopathy Study. Ann Epidemiol 1994−4:67—74.
- Coughlin S., Tefft M. The epidemiology of idiopathic dilated cardiomyopathy in β’ women: The Washington DC Dilated Cardiomyopathy Study. Epidemiology 1994−5:449−55.
- Curb J., Rodriguez B., Burchfiel C., et al. Sudden death, impaired glucose tolerance, and diabetes in Japanese American men. Circulation 1995 -91:2591—5.
- Davi G., Catalano I., Averna M., et al. Thromboxane biosynthesis and platelet function in type II diabetes mellitus. N Engl J Med 1990−322:1769−74.
- Davis M., Bland J., Hangarthner J., et al. Factors influencing the presence or absence of acute coronary artery thrombi in sudden ischemic death. Eur Heart J 1989−10:203−8.
- Davis C. 3rd, Sherman A., Yarochenko Y., et al. Coronary vascular responsiveness to adenosine is impaired additively by blockade of nitric oxide synthesis and sulfonylurea. J Am Coll Cardiol 1998−31:816−22.
- Deedwania P. The deadly quartet revisited. Am J Med 1998−105:1S—3S.
- Depre C., Vanoverschelde J., Taegtmeyer H. Glucose for the heart. Circulation 1999−99:578−88.
- Despres J., Lamarche B., Mauriege P., et al. Hyperinsulinemia as an independent risk factor for ischemic heart disease. N Engl L Med 1996−334:952—7.
- Detry J. the pathophysiology of myocardial ischemia. Eur Heart J 1996-(Suppl G):48—52.
- Di Bello V., Talarico L., Picano E., et al. Increased echodensity of myocardial wall in the diabetic heart: An ultrasound tissue characterization study. J Am Coll Cardiol 1995−25:1408−15.
- Di Carli M., Bianco-Battles D., Landa M., et al. Effects of autonomic neuropathy on coronary blood flow in patients with diabetes mellitus. Circulation 1999−100:813−9.
- Di Carli M., Tobes M., Mangner T., et al. Effects of cardiac sympathetic innervation on coronary blood flow. N Engl J Med 1997−336:1208−15.
- Efficacy of atenolol and Captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. UK Prospective Diabetes Study Group. BMJ 1998−317:713−20.
- Engler R., Yellon D. Sulfonylurea KATP blockade in type II diabetes and preconditioning in cardiovascular disease. Time for reconsideration. Circulation 1996−94:2297−301.
- Estacio R., Jeffers B., Havranek E., et al. Deletion polymorphism of the angiotensin converting enzyme gene is associated with an increase in left ventricular mass in men with type 2 diabetes mellitus. Am JHypertens 1999- 12:637—42.
- Estacio R., Schrier R. Antihypertensive therapy in type 2 diabetes: Implications of the appropriate blood pressure control in diabetes (ABCD) trial. Am J Cardiol 1998−82:9R—14R.
- Evans M., Anderson R., Graham J., et al. Ciprofibrate therapy improves endothelial function and reduces postprandial lipemia and oxidative stress in type 2 diabetes mellitus. Circulation 2000−101:1773−9.
- Ewing D. Cardiac autonomic neuropathy. In: Jarret R., ed. Diabetes and heart disease. Amsterdam: Elsevier, 1984:99—132.
- Factor S., Okun E., Minase T. Capillary microaneurysms in the human diabetic heart. N Engl I Med 1980−302:384−8.
- Faerman I., Faccio E., Milei J., et al. Autonomic neuropathy and painless myocardial infarction in diabetic patients. Histologic evidence of their relationship. Diabetes 1977−26:1147−58.
- Fard A., Tuck C., Donis J., et al. Acute elevation of plasma asymmetric dimethy-larginine and impaired endothelial function in response to a high-fat meal in patients with Type 2 diabetes. Arterioscler Thromb Vase Biol, in press.
- Fava S., Aquilina O., Azzopardi J., et al. The prognostic value of blood glucose in diabetic patients with acute myocardial infarction. Diabet Med 1996- 13:80—3.
- Feener E., King G. Vascular dysfunction in diabetes mellitus. Lancet 1997−350(Suppl 1):9—13.
- Fein F., Sonnenblick E. Diabetic cardiomyopathy. Cardiovasc Drugs Ther 1994−8:65−73.
- Fein F., Sonnenblick E. Diabetic cardiomyopathy. Prog Cardiovasc Dis 1985−27:255−70.
- Fischer V., Barner H., Leskiw M. Capillary basal laminar thickness in diabetic human myocardium. Diabetes 1979−28:713—9.
- Fisher B., Frier B. Evidence for a specific heart disease of diabetes in humans. Diabetic Med 1990−7:478−89.
- Friesinger G. 2nd, Gavin J. 3rd. Diabetes and cardiologist: A call to action. J Am Coll Cardiol 2000−35:1130—3.
- Galderisi M., Anderson K., Wilson P., et al. Echocardiographic evidence for the existence of a distinct diabetic cardiomyopathy (The Framingham Heart Study). Am J Cardiol 1991−68:85−9.
- Garratt K., Brady P., Hassinger N., et al. Sulfonylurea drugs increase early mortality in patients with diabetes mellitus after direct angioplasty for acute myocardial infarction. J Am Coll Cardiol 1999−33:119—24.
- Gerami A., VlassaraH., Brownlee M. Glucose and aging. Sci Am 1987−256:90−6.
- Giles T., Ouyang J., Kerut E., et al. Changes in protein kinase C in early cardiomyopathy and in gracilis muscle in the BB/Wor diabetic rat. Am J Physiol 1998−274:H295—H307.
- Giugliano D., Marfella R., Quatraro A., et al. Tolrestat for mild diabetic neuropathy. A 52-week, .randomized, placebo-controlled trial. Ann Intern Med 1993−118:7−11.
- Gotzsche O., Darwish A., Hansen L., et al. Abnormal left ventricular diastolic function during cold pressor test in uncomplicated insulin-dependent diabetes mellitus. Clin Sci (Colch) 1995−89:461−5.
- Gowri M., Van der. Westhuyzen D., Bridges S., et al. Decreased protection by HDL from poorly controlled type 2 diabetic subjects against LDL oxidation may be due to the abnormal composition of the HDL. Arterioscler Thromb Vase Biol 1999−19:2226−33.
- Gray R., Fabsitz R., Cowan L., et al. Risk factor clustering in the insulin resistance syndrome: The. Strong Heart Study. Am J Epidemiol 1998- 148:869—78.
- Gress T., Nieto F., Shahar F., et al. Hypertension and hypertensive therapy as risk factors for type 2 diabetes mellitus. Atherosclerosis Risk in Communities Study. N Engl J Med 2000−342:905−12.
- Grundy S., Benjamin I., Burke G., et al. Diabetes and cardiovascular disease: A statement for healthcare professionals from the American Heart Association. Circulation 1999- 100:1134—46.
- Gu K., Cowie C., Harris M. Diabetes and decline in heart disease mortality in US adults. JAMA 1999−281:1291−7.
- Gwilt D., Petri M., Lewis P., et al. Myocardial infarction size and mortality in diabetic patients. Br Heart J 1985−54:466−72.
- Haffner S., Lehto S., Ronnemaa T, et al. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl L Med 1998−339:229—34.
- Haffner S., Stern M., Hazuda H., et al. Cardiovascular risk factors in confirmed prediabetic individuals: Does the clock for coronary heart disease start ticking before the oncet of clinical diabetes? JAMA 1990−263:2893−8.
- Hanefeld M., Koehler C., Schaper F., et al. Postprandial plasma glucose is an independent risk factor for increased carotid intima-medial thickness in non-diabetic individuals. Atherosclerosis 1999−144:229—35.
- Hardin N. The myocardial and vascular pathology of diabetic cardiomyopathy. Coron Art Disease 1996−7:99−108.
- Harpaz D., Gottlieb S., Graff E., et al. Effects of aspirin treatment on survival in non-insulin-dependent diabetic patients with coronary artery disease. Israeli Bezafibrate Infarction Prevention Study Group. Am J Med 1998- 105:494—9.
- Harris M. Diabetes in America: Epidemiology and scope of the problem. Diabetes Care 1998−21(Suppl 3):C11—C4.
- Harris M., Flegal K., Cowie C., et al. Prevalence of diabetes, impaired fasting glucose, and impaired glucose tolerance in U.S. adults. The Third National Health and Nutrition Examination Survey, 1988—1994. Diabetes Care 1998−21:518−24.
- Herings R., deBoer A., Strieker B., et al. Hypoglycaemia associated with the use of inhibitors of angiotensin-converting enzyme. Lancet 1996−345:1195—8.
- Hjalmarson A., Gilpin E., Nicod P., et al. Differing circadian patterns of symptom onset in subgroups of patients with acute myocardial infarction. Circulation 1989−80:267−75.
- Ho K., Pinsky J., Kannel W., Levy D. The epidemiology of heart failure: The Framingham Study. J Am Coll Cardiol 1993−22(Suppl A):6—13.
- Hopkins P., Hunt S., Wu S., et al. Hypertension, dyslipidemia, and insulin resistance: Links in a chain or spokes on a wheel? Curr Opin Lipidol 1996−7:241—53.
- Howard G., O’Leary D., Zaccaro D., et al. Insulin sensitivity and atherosclerosis. The Insulin Resistance Atherosclerosis Study (IRAS) Investigators. Circulation 1996−93:1809−17.
- Ikeda T., Iwata K., Tanaka Y. Long-term effect of epalrestat on cardiac autonomic neuropathy in subjects with non-insulin-dependent diabetes mellitus. Diabetes Res ClinPract 1999−43:193−8.
- Imperatore G., Riccardi G., Iovine C., et al. Plasma fibrinogen: A new factor of the metabolic syndrome. A population-based study. Diabetes Care 1998−21:649—54.
- Influence of diabetes on 5-year mortality and morbidity in randomized trial comparing CABG and PTC A in patients with multi vessel disease: The Bypass Angioplasty Revascularisation Investigation (BARI). Circulation 1997−96:1761—9.
- Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK. Prospective Diabetes Study (UKPDS) Group. Lancet 1998−352:837−53.
- Ishii H., Jirousek M., Koya D., et al. Amelioration of vascular dysfunctions in diabetic rats by an oral PKC beta inhibitor. Science 1996−272:728—31.
- Ito A., Tsao P., Adimoolam S., et al. Novel mechanism for endothelial dysfunction: Dysregulation of dimethylarginine dimethylaminohydrolase. Circulation 1999−99:3092−5.
- Ito H., Hiroe M., Hirata Y., et al. Insulin-like growth factor-I induces hypertrophy with enhanced expression of muscle specific genes in cultured rat cardio-myocytes. Circulation 1993−87:1715—21.
- Iwasaka T., Takahashi N., Nakamura S., et al. Residual left ventricular pump function after acute myocardial infarction in NIDDM patients. Diabetes Care 1992−15:1522−6.
- Jaarsma W., Visser C., van Eenige M., et al. Prognostic implications of regional hyperkinesia and remote asynergi of non-infarcted myocardium. Am J Cardiol 1986−58:394−8.
- Jain A., Avendano G., Dharamsey S., et al. Left ventricular diastolic function in hypertension and role of plasma glucose and insulin. Comparison with diabetic heart. Circulation 1996−93:1396−1402.
- Jonas M., Reicher-Reiss H., Boyko V., et al. Usefulness of beta-blocker therapy in patients with non-insulin-dependent diabetes mellitus and coronary artery disease. Bezafibrate Infarction Prevention (BIP) Study Group. Am J Cardiol 1996−77:1273−7.
- Johnstone M., Greager S., Scales K., et ah Impaired endothelium-dependent vasodilation in patients with insulin-dependent diabetes mellitus. Circulation 1993−88:2510−6.
- Kahn J., Sisson J., Vinik A. QT interval prolongation and sudden cardiac death in diabetic autonomic neuropathy. J Clin Endocrinol Metab 1987−64:751—4.
- Kannel W., Hjortland M., Castelli W. Role of diabetes in congestive heart failure: The Framingham study. Am J Cardiol 1974−34:29—34.
- Kannel W., McGee D. Diabetes and cardiovascular disease. The Framingham study. JAMA 1979−241:2035−8.
- Katsuda Y., Egashira K., Ueno H., et al. Glibenclamide, a selextive inhibitor of ATP-sensitive K+ channels, attenuates metabolic coronary vasodilation induced by pacing tachycardia in dogs. Circulation 1995−92:511—7.
- Kawaguchi M., Techigawara M., Ishihata T., et al. A comparison of ultrastructural changes on endomyocardial biopsy specimens obtained from patients with and without hypertension. Heart Vessels 1997- 12:267—74.
- Kawate R., Yamakido M., Nishimoto Y., et al. Diabetes mellitus and its vascular complications in Japanese migrants on the island of Hawaii. Diabetes Care 1979−2:161−70.
- Keyl C., Lemberger P., Palitzsch K., et ah Cardiovascular autonomic dysfunction and hemodynamic response to anesthetic induction in patients with coronary artery disease and diabetes mellitus. Anesth Analg 1999−88:985—91.
- Klein R., Klein B., Moss S. The Wisconsin Epidemiological Study of Diabetic Retinopathy. XVI. The relatioship of C-peptide to the incidence and progression of diabetic retinopathy. Diabetes 1995−44:796−801.
- Klieger R., Miller J., Bigger J.} Moss A. Decreased heart rate variability and its association with increased mortality after acute myocardial infarction. Am J Cardiol 1987−59:256−612.
- Kontopoulus A., Athyros V., Didangelos T., et al. Effect of chronic quinapril administration on heart rate variability in patients with diabetic autonomic neuropathy. Diabetes Care 1997−20:355—61.
- Kornowski R., Mintz G., Kent K., et al. Increased restenosis in diabetes mellitus after coronary interventions is due to exaggerated intimal hyperplasia. A serial intravascular ultrasound study. Circulation 1997−95:136—9.
- Koya D., King G. Protein kinase C activation and the development of diabetic complications. Diabetes 1998−47:859−66.
- Kuboki K., Jiang Z., Takahara N., et al. Regulation of endothelial constitutive nitric oxide synthase gene expression in endothelial cells and in vivo: A specific vascular action of insulin. Circulation 2000- 101:676—81.
- Kuusisto J., Mykkanen L., Pyorala K., et al. Non-insulin-dependent diabetes and its metabolic control are important predictors of stroke in elderly subjects. Stroke 1994−25:1157−64.
- Kubota I., Yamaki M., Shibata T., et al. Role of ATR-sensitive K+ channel on ECG ST segment elevation during a bout of myocardial ischemia. A study on epicardial mapping in dogs. Circulation 1993−88:1845—51.
- Langer A., Freeman M., Josse R., et al. Metaiodobenzylguanidine imaging in diabetes mellitus: Assessment of cardiac sympathetic denervation and its relationto autonomic dysfunction and silent myocardial ischemia. J Am Coll Cardiol 1995−25:610−8.
- Laoby R., Nesto R. Acute myocardial infarction in the diabetic patients: Pathophysiology, clinical course and prognosis. J Am Coll Cardiol 1992−20:736—44.
- Lehto S., Ronnemaa T., Haffner S., et al. Dyslipidemia and hyperglycemia predict coronary heart disease events in middle-aged patients with NIDDM. Diabetes 1997−46:1354−9.
- Levine G., Jacobs A., Keeler G., et al. Impact of diabetes mellitus on percutaneous revascularization (CAVEAT-I). CAVEAT-I Investigators. Coronary Angioplasty Versus Excisional Atheroectomy Trial. Am J Cardiol 1997−79:748—55.
- Libby P., Rabbani L., Brogi E., et al. The challenge of diabetic vascular disease. In Bagdade J. (ed.): Year Book of Endocrinology. St. Louis, Mosby, 1993.
- Lowe L., Liu K., Greenland P., et al. Diabetes, asymptomatic hyperglycemia, and 22-year mortality in black and white men. The Chicago Heart Association Detection Project in Industry Study. Diabetes Care 1997−20:163—9.
- Lucas L., Tsueda K. Cardiovascular depression after brachial plexus block in two diabetic patients with renal failure. Anesthesiology 1990−73:1032—5.
- Lundback K. Diabetic angiopathy: A specific vascular disease. Lancet 1954−2:377−9.
- Malik R. Can diabetic neuropathy be prevented by angiotensin-converting enzyme inhibitors? Ann Med 2000−32:1—5.
- Malmberg K., Herlitz J., Hjalmarsson A., Ryden L. Effects on metoprolol on mortality and late infarction in diabetics with suspected acute myocardial infarction. Retrospective data from two large scale studies. Eur Heart J1989- 10:423—8.
- Malmberg K., Ryden L., Hamsten A., et al. on behalf of the DIGAMI study group. Effects of insulin on cause-specific one-year mortality and morbidity in diabetic patients with acute myocardial infarction. Eur Heart J1996- 17:1337—44.
- Manske C., Wilson R., Wang Y., et al. Atherosclerotic vascular complications in diabetic transplant candidates. Am J Kidney Dis 1997−29:601—7.
- Manson J., Colditz G., Stampfer M., et al. A prospective study of maturity-onset diabetes mellitus and risk of coronary heart disease and stroke in women. Arch Intern Med 1991- 151:1141—7.
- Marchant B., Umachandran V., Stevenson R., et al. Silent myocardial ischemia: Role of subclinical neuropathy in patients with and without diabetes. J Am Coll Cardiol 1993−22:1433—7.
- Margolis J., Kannel W., Feinlieb M., et al. Clinical features of unrecognised myocardial infarctions — silent and symptomatic. Am J Cardiol 1973−32:1—7.
- McVeigh G., Brennan G., Johnston G., et al. Impaired endothelium-dependent and endothelium-independent vasodilation in patients with type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia 1992−35:771—6.
- Meigs J., Mittleman M., Nethan D., et al. Hyperinsulinemia, hyperglycemia, and impaired hemostasis: The Framingham Offspring Study. JAMA 2000−221—8.
- Mildenerger R., Bar-Shlomo B., Druck M., et al. Clinically unrecognized ventricular dysfunction in young diabetic patients. J Am Coll Cardiol 1984−4:234—8.
- Mokdad A., Serdula M., Dietz W., et al. The spread of the obesity epidemic in the United States, 1991—1998. JAMA 1999−282:1519−22.
- Moreno P., Fallon J., Murcia A., et al. Tissue characteristics of restenosis after percutaneosus transluminal coronary angioplasty in diabetic patients. J Am Coll Cardiol 1999−34:1045−9.
- Morris A., Boyle D., McMahon A., et al. ACE inhibitor use is associated with hoospitalisation for severe hypoglycaemia in patients with diabetes. Diabetes Care 1997−20:1363−79.
- Morning peak in the incidence of myocardial infarction: Experience in the ISIS-2 trial. (Second International Study of Infarct Survival) Collaborative Group. Eur Heart J1992- 13:594—8.
- Moye L., Pfeffer M., Wun C., et al. Uniformity of captopril benifit in the SAVE study: Subgroup analysis. Survival and ventricular enlargement study. Eur Heart J 1994−15(Suppl B):2—8.
- Muller J., Toiler G., Stone P. Circadian variation and triggers of onset of acute cardiovascular disease. Circulation 1989−79:733—43.
- Mustonen J., Uusitupa M., Laakso M., et al. Left ventricular systolic function in middle-aged patients with diabetes mellitus. Am J Cardiol 1994−73:1202—8.
- Nahser P. Jr, Brown R., Oskarsson H., et al. Maximal coronary flow reserve and metabolic coronary vasodilation in patients with diabetes mellitus. Circulation 1995−91:635−40.
- Nathan D. Long-term complications of diabetes mellitus. N Engl J Med 1993−328:1676−85.
- Nathan D., Meigs J., Singer D. The epidemiology of cardiovascular disease in type 2 diabetes mellitus: how sweet it is. or is it? Lancet 1997−350(Suppl 1):4—9.
- Nesto R. Screening for asymptomatic coronary artery disease in diabetes. Diabetes Care 1999−22:1393−5.
- Nesto R., Phillips R., Kett K., et al. Angina and exertional myocardial ischemia in diabetic and nondiabetic patients: Assessment by exercise thallium scintigraphy. Ann Intern Med 1988- 108:170—5.
- Nesto R., Zarich S. Acute myocardial infarction in diabetes mellitus: Lessons learned from ACE inhibition. Circulation 1998−97:12—5.
- Nikan E., Harati Y., Comstock J., Rhey R. Silent myocardial infarction and diabetic cardiovascular autonomic neuropathy. Arch Intern Med 1986- 146:2229—30.
- O’Leary D., Polak J., Kronmal R., et al. Carotid-artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults. Cardiovascular Health Study Collaborative Research Group. N Engl J Med 1999−340:14−22.
- Orchard T., Lloyd C., Maser R., Kuller L. Why does diabetic autonomic neuropathy predict IDDM mortality? An analysis from the Pittsburgh Epidemiology of Diabetes Complications Study. Diabetes Res Clin Pract 1996−34(Suppl):165—71.
- Oswald G., Smith C., Betteridge D., et ah Determinants and importance of stress hyperglycaemia in non-diabetic patients with myocardial infarction. BMJ 1986−293:917−22.
- Paillole C., Dahan M., Payche F., et al. Prevalence and significance of left ventricular filling abnormalities determined by Doppler echocardiography in young type I (insulin-dependent) diabetic) patients. Am J Cardiol 1990−64:1010—6.
- Park L., Raman K., Lee K., et al. Suppression of accelerated diabetic atherosclerosis by the soluble receptor for advanced glycation end products. Nat Med 1998−4:1025−31.
- Perez J, McGill J., Santiago JV, et al. Abnormal myocardial acoustic properties in diabetic patients and their correlation with the severity of disease. J Am Coll Cardiol 1992- 19:1154—62.
- Petrie J., Ueda S., Webb D., et al. Endothelial nitric-oxide production and insulin sensitivity. A physiological link with implications for pathogenesis of cardiovascular disease. Circulation 1996−93:1331—3.
- Pfeffer M., Braunwald E., Moye L., et al., on the behalf of the SAVE investigators. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 1992−327:669—77.
- Pfeffer M., Greaves S., Arnold J., et al. Early versus delayed angiotensin-converting-enzyme inhibition therapy in acute myocardial infarction. The healing and early afterload reducing therapy trial. Circulation 1997−95:2643—51.
- Platelet glycoprotein Ilb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. The EPILOG Investigators. N Engl J Med 1997−336:1689−96.
- Pozzati A., Pancaldi L., Di Pasquale G., et al. Transient sympathovagal imbalance triggers «ischemic» sudden death in patients undergoing electrocardiographic Holter monitoring. J Am Coll Cardiol 1996−27:847−52.
- Prevalence of unrecognised silent myocardial ischemia and its association with atherosclerotic risk factors in non-insulin-dependent diabetes mellitus. Milan Study on Atherosclerosis and Diabetes (MiSAD) Group. Am J Cardiol 1997−79:134−9.
- Raev D. Witch left ventricular function is impaired earlier in the evolution of diabetic cardiomyopathy? An echocardiographic study of young type I diabetes patients. Diabetes Care 1994- 17:633—9.
- Reaven G. Role of insulin resistance in human disease (syndrome X): An expanded definition. Annu Rev Med 1993 -44:121 —31.
- Reaven G., Laws A. insulin resistance, compensatory hyperinsulinemia and coronary artery disease. Diabetologia 1994−37:948—52.
- Reaven G., Lithell H., Landsberg L. Hypertension and associated metabolic abnormalities — the role on insulin resistance and the sympathoadrenal system. N Engl L Med 1996−334:374−81.
- Reis S., Holubkov R., Edmundowicz D., et al. treatment of patients admitted to hospital with congestive heart failure: Speciality-related discrepancies in practice patterns and outcomes. J Am Coll Cardiol 1997−30:733—8.
- Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 1999−22(Suppl 1):5—19.
- Rodriguez B., Cam M., McNeill J. Metabolic disturbances in diabetic cardiomyopathy. JMol Cell Biol Biochem 1998−180:53−7.
- Rodriguez B., Cam M., McNeill J. Myocardial substrate metabolism: Implications for diabetic cardiomyopathy. JMol Cell Cardiol 1995−27:169—79.
- Sampson M., Wilson S., Karagiannis P., et al. Progression of diabetic autonomic neuropathy over decade in insulin-dependent diabetics. Q J Med 1990−75:635−46.
- Sasson Z., Rasooly Y., Bhesania T., et al. Insulin resistance is an important determinant of left ventricular mass in the obese. Circulation 1993−88:1431—6.
- Schindler D., Kostis J., Yusuf S., et al. for the SOLVD investigators. Diabetes mellitus: A predictor of morbidity and mortality in the studies of left ventricular dysfunction (SOLVD) trials and registry. Am J Cardiol 1996−77:1017−20.
- Schmidt A., Yan S., Wautier J., et al. Activation of receptor for advanced gly-cation end products: A mechanism for chronic vascular dysfunction in diabetic vasculopathy and atherosclerosis. CircRes 1999−84:489—97.
- Schwartz C., Valente A., Sprague E., et al. Pathogenesis of the atherosclerotic lesion: Implications for diabetes mellitus. Diabetes Care 1992−15:1156—67.
- Scognamiglio R., Avogaro A., Casara D., et al. Myocardial dysfunction and adrenergic cardiac innervation in patients with insulin-dependent diabetes mellitus. J Am Coll Cardiol 1998−31:404—12.
- Selby J., Ray G., Zhang D., et al. Excess cost of medical care for patients with diabetes in a managed care population. Diabetes Care 1997−20:1396—1402.
- Shiotani H., Ueno H., Inoue S., et al. Diabetes mellitus and cardiomyopathy— association with mutation in the mitochondrial t-RNA (Leu)(UUR) gene. Jpn Circ 1998−62:309−10.
- Shorr R., Ray W., Daugherty J., et al. Antihypertensives and the risk of serious hypoglycemia in older persons using insulin or sulfonylureas. JAMA 1997−278:40−3.
- Silva J., Escobar A., Collins T., et al. Unstable angina: A comparison between diabetic and non-diabetic patients. Circulation 1995−92:1731—6.
- Singer D., Moulton A., Nathan D. Diabetic myocardial infarction. Interaction of diabetes with other preinfarction risk factors. Diabetes 1989−38:350—7.
- Solang L., Malmberg K., Ryden L. Diabetes mellitus and congestive heart failure. Eur Heart J 1999−20:789−95.
- Soulis-Liparota T., Cooper M., Papazoglou D., et al. Retardation by amino-guanidine of development of albuminuria, mesangial expansion, and tissue fluorescence in streptozocin-induced diabetic rat. Diabetes 1991 -40:1328—34.
- Spallone V, Maiello M., Cicconetti E, et al. Autonomic neuropathy and cardiovascular risk factors in insulin-dependent and non insulin-dependent diabetes. Diabetes Res Clin Pract 1997−34:169−79.
- Spallone V., Menzinger G. Diagnosis of cardiovascular autonomic neuropathy in diabetes. Diabetes 1997−46(Suppl 2):67—76.
- Stamler J., Vaccaro O., Neaton J., et al. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 1993−16:434−44.
- Standi E., Balletshofer B., Dahl B., et al. Predictors of 10-year macrovascular and overall mortality in patients with NIDDM: The Munich General Practitioner Project. Diabetologia 1996−39:1540−5.
- Stein B., Weintraub W., Geibhart S., et al. Influence of diabetes mellitus on early and late outcome after percutaneous transluminal coronary angioplasty. Circulation 1995−91:979−89.
- Steinberg H., Chaker H., Learning R., et al. Obesity/insulin resistance is associated with endothelial dysfunction. Implications for the syndrome of insulin resistance. J Clin Invest 1996−97:2601−10.
- Steiner G. Lipid intervention trials in diabetes. Diabetes Care 2000−23(Suppl 2):B49—53.
- Stevens M., Dayanikli F., Raffel D., et al. Scintigraphic assessment of regionalized defects in myocardial sympathetic innervation and blood flow regulation in diabetic patients with autonomic neuropathy. J Am Coll Cardiol 1998−31:1575—84.
- Stevens M., Raffel D., Allman K., et al. Cardiac sympathetic dysinnervation in diabetes: Implications for enhanced cardiovascular risk. Circulation 1998−98:961−8.
- Stevens M., Raffel D., Allman K., et al. Regression and progression of cardiac sympathetic dysinnervation complicating diabetes: An assessment by C-ll hy-droxyephedrine and positron emission tomography. Metabolism 1999−48:92—101.
- Stitt A., Bucala R., Vlassara H. Atherogenesis and advanced glycation: Promotion, progression, and prevention. Ann N YAcad Sci 1997−811:115—27.
- Suskin N., McKelvie R., Roteaus J., et al. Increased insulin anf glucose levels in heart failure. J Am Coll Cardiol 1998−3(Suppl):249A.
- Takahashi N., Iwasaka T. Left ventricular regional function after acure anterior myocardial infarction in diabetic patients. Diabetes Care 1989−12:630—5.
- Takeda N. Mitochondrial DNA mutations in diabetic heart. Diabetes Res Clin Pract 1996−31(Suppl):123—6.
- Tatti P., Pahor M., Byington R., et al Outcome results of the Fosinopril Versus Amlodipine Cardiovascular Events Randomized Trial (FACET) in patients with hypertension and NIDDM. Diabetes Care 1998−21:597−603.
- Temelkova-Kurktschiev T., Koehler C., Leonhardt W., et al. Increased intimal-medial thickness in newly detected type 2 diabetes: Risk factors. Diabetes Care 1999−22:333−8.
- Terry C., Callahan K. Protein kinase C regulates cytokine-induced tissue factor transcription and procoagulant activity in human endothelial cells. J Lab Clin Med 1996−127:81−93.
- Tesfamariam B., Cohen R. Free radicals mediate endothelial cell dysfunction caused by elevated glucose. Am J Physiol 1992−263:H321—H6.
- The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl L Med 1993−329:977−86.
- The Expert Committee on the Diagnosis and Classification of Diabetes Melli-tus. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 1997−20:1183—202.
- The NETWORK investigators. Clinical outcome with enalapril in symptomatic chronic heart failure: A dose comparison. Eur Heart J 1998- 19:481—9.
- The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fraction and congestive heart failure. N Engl L Med 1991−325:293−302.
- The SOLVD Investigators. Effect of enalapril on mortality and development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl L Med 1992−327:685−91.
- The Task Force of the European Society of Cardiology. Guidelines for the diagnosis of heart failure. Eur Heart J1995- 16:741—51.
- The Task Force of the European Society of Cardiology. Guidelines for the treatment of heart failure. Eur Heart J 1997−18:736—53.
- Timimi F., Ting H., Haley E., et al. Vitamin C improves endothelium-dependent vasodilation in patients with insulin-dependent diabetes mellitus. J Am Coll Cardiol 1998−31:552−7.
- Tominaga M., Eguchi H., Manaka H., et al. Impaired glucose tolerance is a risk factor for cardiovascular disease, but not impaired fasting glucose. The Funa-gata Diabetes Study. Diabetes Care 1999−22:920—4.
- Torlone E., Britta M., Rambotti A., et al. Improved insulin action and glycemic control after long-term angiotensin-converting-enzyme inhibition in subjects with arterial hypertension and type II diabetes. Diabetes Care 1993- 16:1347—55.
- Toyry J., Niskanen L., Mantysaari M., et al. Occurrence, predictors, and clinical significance of autonomic neuropathy in NIDDM. Ten-year follow-up from the diagnosis. Diabetes 1996−45:308−15.
- Trovati M., Anfossi G. Insulin, insulin resistance and platelet function: Simi-Β¦larities with insulin effects on cultured vascular smooth muscle cell. Diabetologia1998−41:609−22.
- Tsai E., Hirsch I., Brunzell J., et al. Reduced plasma peroxyl radical trapping capacity and increased susceptibility of LDL to oxidation in poorly controlled IDDM. Diabetes 1994−43:1010—4.
- Tuomilehto J., Rastenyte D., Birkenhager W., et al. Effects of calcium-channel blockade in older patients with diabetes and systolic hypertension. Systolic Hypertension in Europe Trial Investigators. N Engl L Med 1999−340:677—84.
- Turner R. The U.K. Prospective Diabetes Study. A review. Diabetes Care 1998−21(Suppl 3):C35—C8.
- U.K. Prospective Diabetes Study Group. Tight blood pressure control and risk of microvascular and microvascular complications in type 2 diabetes: UKPDS 38. Br Med J 1998−317:703−13.
- Vigorita V., Morre G., Hutchens G. Absence of correlation between coronary arterial atherosclerosis and severity or duration of diabetes mellitus of adult onset. Am J Cardiol 1980−46:535−42.
- Vlassara H. Protein glycation in the kidney: Role in diabetes and aging. Kidney Int 1996−49:1795−804.
- Vlassara H., Fuh H., Donnelly T., et al. Advanced glycation end products promote adhesion molecule (VCAM-1, ICAM-1) expression and atheroma formation in normal rabbits. Mol Med 1995- 1:557—56.
- Vlassara H., Fuh H., Makita Z., et al. Exogenous glycosylation end products induce complex vascular dysfunction in normal animals: A model for diabetic and aging complications. Proc Natl Acad Sci USA 1992−89:12 043−7.
- Wagenknecht L., D’Agostino R., Haffner S., et al. Impaired glucose tolerance, type 2 diabetes, and carotid wall thickness: The Insulin Resistance Atherosclerosis Study. Diabetes Care 1998−21:1812—8.
- Wakasaki H., Koya D., Schoen F., et al. Targeted overexpression of protein kinase C beta2 isoform in myocardium causes cardiomyopathy. Proc Natl Acad Sci USA 1997−94:9320−5.
- Warram J., Laffel L., Valsania P., et al. Excess mortality associated with diuretic therapy in diabetes mellitus. Arch Intern Med 1991- 151:1350—6.
- Weintraub W., Stein B., Kosinski A., et al. Outcome of coronary bypass surgery versus coronary angioplasty in diabetic patients with multivessel coronary artery disease. J Am Coll Cardiol 1998−31:10−9.
- Wautier J., Guillausseau P. Diabetes, advanced glycation end products and vascular disease. Vase Med 1998−3:131—7.
- Wei K., Dorian P., Newman D., et al. Association between QT dispersion autonomic dysfunction in patients with diabetes mellitus. J Am Coll Cardiol 1995−26:859−63.
- Wei M., Gaskill S., Haffner S., et al. Effects of diabetes and level of glycemia on all-cause and cardiovascular mortality. The San Antonio Heart Study. Diabetes Care 1998−21:1167−72.
- Williams S., Cusco J., Roddy M., et al. Impaired nitric-oxide-mediated vasodilation in patients with non-insulin-dependent diabetes mellitus. J Am Coll Cardiol 1996−27:567−74. '
- Wilson P., Kannel W., Silbershatz H., et al. Clustering of metabolic factors and coronary artery disease. Arch Intern Med 1999- 159:1104—9. :
- Wingard D., Barrett-Connor E. Heart disease in diabetes. In: Harris M., Cowie C., Stern M., et al., eds. Diabetes in America. 2nd edn. Washington DC: U.S. Government Printing Office, 1995:429—48.
- Wingard D., Barrett-Connor E., Scheidt-Nave C., et al. Prevalence of cardiovascular and retinal complications in older adults with normal or impaired glucose tolerance or NIDDM. A population-based study. Diabetes Care 1993- 16:1022—5.
- Witztum J. Role of modified lipoproteins in diabetic macroangiopathy. Diabetes 1997−46(Suppl 2):112—4.
- Woodfield S., Lundergan C., Reiner J., et al. Angiographic findings and outcome in diabetic patients treated with thrombolytic therapy for acute myocardial infarction: the GUSTO-I experience. J Am Coll Cardiol 1996−28:1661−9.
- Yusuf S., Sleight P., Pogue J., et al. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000−342:145−53.
- Zarich S., Arbuckle Π., Cohen L., et al. Diastolic abnormalities in young asymptomatic diabetic patients assessed by pulsed Doppler echocardiography. J Am Coll Cardiol 1988−12:114−20.
- Zarich S., Nesto R. Diabetic cardiomyopathy. Am Heart J1989- 118:1000—12.
- Zarich S., Waxman R., Freeman R., et al. Effect of autonomic nervous system dysfunction on the circadian pattern of myocardial ischemia in diabetes mellitus. J Am Coll Cardiol 1994−24:956−62.
- Ziegler D., Dannehl K., Volksw D., et al. Prevalence of cardiovascular autonomic dysfunction assessed by spectral analysis and standard tests of heart-rate variation in newly diagnosed IDDM patients. Diabetes Care 1992- 15:908—-11.
- Zuanetti G., Latini R., Maggiono A., et al. effect of the ACE inhibitor lisinopril on mortality in diabetic patients with acute myocardial infarction. Data from the GISSI 3 study. Circulation 1997−96:4239−45.1. Π ΡΠ°Π·Π΄Π΅Π»Ρ II:
- American Diabetes Association: Physician"s guide to non-insulin-dependent (Type II) DiabetesA diagnosis and treatment, 2 nd ed. Alexandria, VA, American Diabetes Association, 1988
- Criteria Committee, New York Heart Association, Inc.: Diseases of the Heart and Blood Vessels. Nomenclature and Criteria for Diagnosis. 6 th ed. Boston, Little, Brown and Co., 1964, p. l 14.
- Rector Π’., Cohn J. Assessment of patient outcome with the Minnesota Living with Heart Failure Questionnaire: Reliability and validity during a randomized, double-blind, placebo controlled trial of pimobendan. Am Heart J 1992- 124:1017.
- Henry W., Gardin J., Ware J. Echocardiographic measurements in normal subjects from infancy to old age. Circulation 1980−62: 1054
- Schiller N. Two-dimensional echocardiographic determination of left ventricular volume, systolic function, and mass. Summary and discussion of the 1989 recommendation of the American Society of Echocardiography. Circulation 84 1991- (Suppl 3): 280
- Ishikura F., Redfield M. Doppler echocardiography assessment of diastolic function in congestive heart failure: emphasis on clinical utility. Heart failure 1998- 14: 78−96
- Belmonte M., Sarkozy E., Harpur E. Urine sugar determination by two drop Clinitest metod. Diabetes 1967- 16: 557.
- Kutter D. A chemical test strip to determine low concentrations of albumin and creatine in urine. Lab Med 1998- 29: 769 72.